Nothing Special   »   [go: up one dir, main page]

EP2982691B1 - Broad spectrum monoclonal antibody identifying ha1 structural domain of influenza virus hemagglutinin proteins - Google Patents

Broad spectrum monoclonal antibody identifying ha1 structural domain of influenza virus hemagglutinin proteins Download PDF

Info

Publication number
EP2982691B1
EP2982691B1 EP14778269.2A EP14778269A EP2982691B1 EP 2982691 B1 EP2982691 B1 EP 2982691B1 EP 14778269 A EP14778269 A EP 14778269A EP 2982691 B1 EP2982691 B1 EP 2982691B1
Authority
EP
European Patent Office
Prior art keywords
monoclonal antibody
antibody
antigen binding
binding fragment
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP14778269.2A
Other languages
German (de)
French (fr)
Other versions
EP2982691A1 (en
EP2982691A4 (en
Inventor
Yixin Chen
Qingbing ZHENG
Rui Li
Chenguang SHEN
Shaojun KE
Wenxin Luo
Honglin Chen
Ningshao Xia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen University
Original Assignee
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen University filed Critical Xiamen University
Publication of EP2982691A1 publication Critical patent/EP2982691A1/en
Publication of EP2982691A4 publication Critical patent/EP2982691A4/en
Application granted granted Critical
Publication of EP2982691B1 publication Critical patent/EP2982691B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Definitions

  • the invention relates to the field of molecular virology, particularly the field concerning vaccines for the prevention of influenza virus.
  • the invention relates to antibodies recognizing epitopes on HA1 domain of hemagglutinin of influenza virus, cell lines for producing the antibodies, and uses thereof.
  • the antibodies according to the invention can specifically bind to HA1 domain of different HA subtypes of Influenza virus and specifically bind to HA1 domain of hemagglutinin (HA) protein of H1 subtype (including seasonal H1N1 and 2009 pandemic H1N1) and H5 subtype of influenza viruses. Therefore, the invention also discloses vaccines or pharmaceutical compositions for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or diseases caused by the infection (e.g. influenza), comprising the antibodies according to the invention.
  • HA hemagglutinin
  • Influenza commonly known as “the flu” is a respiratory infectious disease caused by the influenza virus, and has the symptoms of high fever, feeling tired, and muscle pains, accompanied by some respiratory symptoms. Influenza virus is a threat to human health, the sustained and rapid antigenic drift cause wide spread of seasonal influenza. According to statistics of WHO, seasonal influenza is responsible for the death of at least 250,000-500,000 persons per year ( Peter D.C. et al., J Clin Invest. 2008, 118:3273-3275 ). In addition, flu outbreak is still an important threat to human beings. Since influenza virus was discovered, flu outbreak occured five times around world in human history, resulting in tens of millions of deaths; among them, Spanish influenza (H1N1) in 1918 resulted in about 20-50 millions of deaths in the world.
  • influenza pandemics occurred in the 20th century also include Asian influenza (H2N2) in 1957 and Hong Kong Influenza (H3N2) in 1968, both of which caused serious public health threat and human social panic ( Xu R. et al., Science. 2010, 328: 357-360 ).
  • influenza outbreaks still do not stop; influenza A (2009 pandemic H1N1) outbreak occurred in Mexico in 2009 and quickly spreaded around the world, which sounded the alarm to human society once again; according to WHO statistics, up to August 6, 2010, a total of 18,449 cases of confirmed deaths were reported in more than 200 countries and regions globally (WHO Pandemic (H1N1) 2009 - update 112. 6 Aug, 2010).
  • Influenza virus is an enveloped, single stranded, negative-sense RNA virus that belongs to the genus influenza virus of the family Orthomyxoviridae. Its genome contains eight segments of RNA, and encode for more than 10 viral proteins. According to the difference in antigenicity and genetic characteristics of nucleoprotein (NP) and matrix protein (M), influenza virus can be classified into Influenza virus A, Influenza virus B, and Influenza virus C ( Horimoto T. et al., Nat Rev Microbiol, 2005, 3(8): 591-600 ). Influenza A Virus (called Flu A for short) mutates fast, has a strong pathogenicity, and can cause worldwide pandemics.
  • NP nucleoprotein
  • M matrix protein
  • Influenza B Virus (called Flu B for short) mutates slow and can only cause small pandemics in local areas.
  • Influenza C Virus (called Flu C for short) mutates slowest, has a weak pathogenicity, and can only infect pregnant women and children with a low resistance generally.
  • Flu A can cause infection in animals such as human, horses and pigs, in addition to its natural host aquatic birds. Flu A has multiple subtypes which are different from each other greatly, and has become a research focus for influenza control and vaccine.
  • Flu A viruses are categorized into subtypes based on the antigenicity and genetic characteristics of the two surface antigens, i.e. hemagglutinin (HA) and neuraminidase (NA).
  • HA hemagglutinin
  • NA neuraminidase
  • H1 to H17 hemagglutinin
  • N1 to N10 NA subtypes
  • the Flu A subtypes epidemic in human beings include two HA subtypes (H1, H3) and two NA subtypes (N1, N2).
  • highly pathogenic avian influenza virus H5N1 only infects human beings occasionally, it draws attention due to the high mortality rate.
  • the first line of defense to prevent influenza is neutralizing antibodies.
  • the vaccine-induced neutralizing antibodies mainly target the membrane protein hemagglutinin (HA) on the surface of virus.
  • HA protein on the surface of virus has a trimeric structure, and each HA monomer consists of HA1 domain and HA2 domain.
  • HA1 forms a globule at the top of the trimer, contains receptor binding sites, and is a region essential for the virus to infect a host cell; HA1 also contains important antigenic sites, can induce generation of protective neutralizing antibodies in organisms, and thus is a key target for vaccine design ( Wang T.T. et al., Nat Struct Mol Biol. 2009, 16: 233-234 ).
  • HA2 is located at the base of the trimer, has a shape of stem, contains fusion peptide, and can mediate the fusion of viral envelope to host cell membrane; and some monoclonal antibodies against HA2 can inhibit the membrane fusion of influenza virus so as to achieve the effect of neutralizing virus ( Wang T.T. et al., Nat Struct Mol Biol. 2009, 16: 233-234 ).
  • Influenza viruses have a high variability, particularly, HA mutates fastest.
  • traditional influenza vaccines are mainly directed to HA protein, and the influenza vaccines become ineffective easily because of virus antigenic drift caused by HA gene mutation.
  • WHO annually needs to monitor the mutation of the influenza virus strains epidemic last year, and select old influenza virus vaccines or establish new influenza virus vaccines as candidate influenza vaccines next year so as to retain the effective protection from epidemic influenza virus strains by inoculation of new vaccines every year. Therefore, development of "universal influenza vaccines" that are not affected by virus mutation becomes a research focus for development of new vaccines.
  • the glycoprotein on the surface of influenza virus i.e.
  • hemagglutinin (HA) is a main target for the development of universal influenza vaccines and immunotherapeutic medicines against influenza virus.
  • the so-called “universal influenza vaccines” should comprise "highly conserved neutralizing epitopes” shared by different viral mutants, and can directly induce the generalization of "broad-spectrum neutralizing antibodies” to combat the infection by different virus mutants. Therefore, an important route for studying universal influenza vaccines and immunotherapeutic medicines against influenza is to look for highly conserved neutralizing epitopes on HA.
  • a humanized HA monoclonal antibody specific to H1N1 and H5N1 has been demonstrated to be able to effectively treat experimental mice infected by influenza virus ( Corti D. et al., J Clin Invest. 2010,120:1663-1673 ).
  • polyclonal antibodies and monoclonal antibodies can be effectively applied to the prevention of infections by viruses such as Hepatitis A Virus, Hepatitis B Virus, rabies virus and respiratory syncytial virus ( Sawyer L.A. et al., Antiviral Res. 2000, 47: 57-77 ).
  • viruses such as Hepatitis A Virus, Hepatitis B Virus, rabies virus and respiratory syncytial virus ( Sawyer L.A. et al., Antiviral Res. 2000, 47: 57-77 ).
  • serum from human in convalescent stage was used for the treatment ( Luke T.C. et al., Ann Intern Med. 2006, 145:599-609 ).
  • Antibodies for preventing or treating influenza infection have been described (see for example WO2010/010467 , US2012/058124 , WO2012/045001 , and WO2013/030604 ).
  • HA broad-spectrum monoclonal antibodies and highly conserved epitopes have been reported in many papers. Studies on broad-spectrum monoclonal antibodies and highly conserved epitopes against HA2 which is more conservative have become a major research focus ( Throsby M. et al., PLoS One. 2009, 3: e3942 ; Sui J. et al., Nat Struct Mol Biol. 2009, 16: 265-273 ; Corti D. et al., J Clin Invest. 2010, 120: 1663-1673 ; Corti D. et al., Science. 2011, 333: 850-856 ). As early as 2009, Throsby et al.
  • HA1 of influenza virus forms a globule at the top of the trimer, contains a lot of neutralizing epitopes, and is easily accessible. Therefore, it is more possible to develop effective universal influenza vaccines and therapeutic antibodies by looking for highly conserved neutralizing epitopes on HA1. Since the subtypes of influenza virus are divided initially based on serotyping of polyclconal antibodies and the pAb serum against one subtype has little cross-reactivity with virus of another subtype, it is generally believed that the neutralizing monoclonal antibodies specific to HA (particularly HA1) are serotype-specific and has no cross-reactivity with HA of another subtype.
  • HA1 has a high variability, the reactive spectrum of the current HA1 monoclonal antibodies is narrow, as compared to that of HA2 monoclonal antibodies, and the HA1 monoclonal antibodies generally have a cross-neutralizing activity for 2-3 subtypes of influenza viruses.
  • Yoshida et al. reported in 2008 that a HA1 broad-spectrum neutralizing monoclonal antibody, S139/1, could neutralize H1, H2, H3 and H13 subtypes of influenza viruses, but the neutralizing activity of the monoclonal antibody was only limited to a few virus strains for each of said subtypes ( Yoshida R. et al., PLoS Pathog. 2009, 5: e1000350 ).
  • HA1 may contain conservative neutralizing epitopes, which are important for the research on universal influenza vaccines and immunotherapeutic medicines.
  • H3 numbering refers to the numbering based on the amino acid sequence of the HA obtained by aligning the HA amino acid sequence of H1N1 virus with the amino acid sequence of HA (with the signal peptide removed) of H3N2 virus strain A/Hong Kong/1/1968 (H3N2) (Genbank: AAK51718.1). Therefore, as used herein, the amino acid residue at position N (such as position 142) of HA refers to the amino acid residue corresponding to the one at position N (such as position 142) of the amino acid sequence of the aligned HA.
  • the term "antibody” generally refers to an immunoglobulin molecule consisting of two pairs of polypeptide chains (each has a light (L) chain and a heavy (H) chain).
  • Light chains of an antibody may be classified into ⁇ and ⁇ light chain.
  • Heavy chains may be classified into ⁇ , ⁇ , ⁇ , ⁇ and ⁇ , which define isotypes of an antibody as IgM, IgD, IgG, IgA and IgE, respectively.
  • a variable region is linked to a constant region via a "J" region of about 12 or more amino acids, and a heavy chain further comprises a "D" region of about 3 or more amino acids.
  • Each heavy chain consists of a heavy chain variable region (V H ) and a heavy chain constant region (C H ).
  • a heavy chain constant region consists of 3 domains (C H 1, C H 2 and C H 3).
  • Each light chain consists of a light chain variable region (V L ) and a light chain constant region (C L ).
  • a light chain constant region consists of a domain C L .
  • the constant region of an antibody can mediate the binding of an immunoglobulin to a host tissue or factor, including various cells (e.g., effector cells) of an immune system and the first component (C1q) of classical complement system.
  • V H and V L region can also be divided into hypervariable regions (called complementary determining regions (CDR)), which are interspaced by relatively conservative regions (called framework region (FR)).
  • CDR complementary determining regions
  • FR framework region
  • Each V H and V L consists of 3 CDRs and 4 FRs in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from N-terminal to C-terminal.
  • the variable region (V H and V L ) of each heavy/light chain pair forms an antigen binding site, respectively. Distribution of amino acids in various regions or domains follows the definition in Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991 )), or Chothia & Lesk (1987) J. Mol. Biol.
  • antibody is not restricted by any specific method for producing antibodies.
  • antibodies include particularly, recombinant antibodies, monoclonal antibodies and polyclonal antibodies.
  • Antibodies may be of different antibody isotypes, for example, IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM antibody.
  • antigen binding fragment of an antibody refers to polypeptides comprising fragments of a full-length antibody, which retain the ability of specifically binding to an antigen that the full-length antibody specifically binds to, and/or compete with the full-length antibody for binding to the same antigen, also known as "antigen binding portion".
  • Antigen binding fragments of an antibody may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of an intact antibody.
  • antigen binding fragments include Fab, Fab', F(ab') 2 , Fd, Fv, dAb and complementary determining region (CDR) fragments, single chain antibody (e.g. scFv), chimeric antibody, diabody and such polypeptides that comprise at least a part of an antibody sufficient to confer the ability of specific binding with the antigen to the polypeptides.
  • CDR complementary determining region
  • Fd fragment refers to an antibody fragment consisting of V H and C H 1 domain
  • Fv fragment refers to an antibody fragment consisting of V L and V H domain of a single arm
  • dAb fragment refers to an antibody fragment consisting of V H domain ( Ward et al., Nature 341:544-546 (1989 ))
  • Fab fragment refers to an antibody fragment consisting of V L , V H , C L and C H 1 domain
  • F(ab') 2 fragment refers to an antibody fragment comprising two Fab fragments linked to each other via disulphide bridge(s) on hinge region.
  • antigen binding fragments of an antibody are single chain antibodies (e.g. scFv), wherein V L and V H domain are paired to form a monovalent molecule via a linker that enables them to produce a single polypeptide chain (see, for example, Bird et al., Science 242:423-426 (1988 ) and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988 )).
  • scFv molecules generally have a common structure: NH 2 -V L -linker-V H -COOH or NH 2 -V H -linker-V L -COOH.
  • Suitable linkers in the prior art consist of repeated GGGGS amino acid sequence or variants thereof.
  • a linker having an amino acid sequence (GGGGS) 4 may be used, and its variants may also be used ( Holliger et al., (1993), Proc. Natl. Acad. Sci. USA 90: 6444-6448 ).
  • Other linkers that may be used in the invention are described by Alfthan et al., (1995), Protein Eng. 8:725-731 , Choi et al., (2001), Eur. J. Immunol. 31: 94-106 , Hu et al., (1996), Cancer Res. 56:3055-3061 , Kipriyanov et al., (1999), J. Mol. Biol. 293:41-56 and Roovers et al., (2001), Cancer Immunol .
  • antigen binding fragments of an antibody may be diabodies, i.e. divalent antibodies, wherein V H and V L domain are expressed on a single polypeptide chain, however, the linker used is too short to allow the pairing of the two domains on the same chain, the domains have to be paired with the complementary domains on another chain to produce two antigen binding sites (see, for example, Holliger P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993 ), and Poljak R. J. et al., Structure 2:1121-1123 (1994 )).
  • Antigen binding fragments e.g. the antibody fragments as described above
  • an antibody may be obtained from a given antibody (e.g., the monoclonal antibody provided in the invention) by conventional techniques known by a person skilled in the art (e.g., recombinant DNA technique or enzymatic or chemical cleavage methods), and may be screened for specificity in the same manner by which intact antibodies are screened.
  • antibody in the invention, unless specified definitely, when the term "antibody” is mentioned, it includes not only intact antibodies, but also antigen binding fragments of the antibodies.
  • mAb and “monoclonal antibody” refer to an antibody or a fragment of an antibody from a population of highly homologous antibody molecules, i.e. a population of completely identical antibody molecules except for natural mutation that may occur spontaneously.
  • a monoclonal antibody has a high specificity for a single epitope of an antigen.
  • Polyclonal antibody, relative to monoclonal antibody generally comprises at least two or more different antibodies which generally recognize different epitopes on an antigen.
  • Monoclonal antibodies are generally obtained by hybridoma technique reported by Kohler et al. for the first time (Nature, 256:495, 1975 ), and can also be obtained by recombinant DNA technique (see, for example, U.S.P 4,816,567 ).
  • monoclonal antibodies may be prepared as follows. Firstly, mice or other suitable host animals are immunized by injection of immunogen (if necessary, adjuvants are added).
  • the injection means of immunogens or adjuvants generally are subcutaneous multi-point injection or intraperitoneal injection. Pre-conjugation of immunogens to some known proteins (e.g. serum albumin or soybean trypsin inhibitor) may promote immunogenicity of antigens in a host.
  • Adjuvants may be Freund's adjuvant or MPL-TDM, etc.
  • lymphocytes secreting antibodies that specifically bind to immunogen are produced in the animal.
  • lymphocytes may be obtained by means of in vitro immunization.
  • Lymphocytes of interest are collected and are fused to myeloma cells using a suitable fusion agent (such as PEG), thereby getting hybridoma cells ( Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103, Academic Press, 1996 ).
  • a suitable fusion agent such as PEG
  • the hybridoma cells prepared above are seeded to a suitable culture medium and grow in the medium, and the culture medium comprises one or more substances capable of inhibiting growth of unfused, parent myeloma cells.
  • HGPRT hypoxanthine guanine phosphoribosyl transferase
  • HAT culture medium substances such as hypoxanthine, aminopterin and thymine
  • Preferred myeloma cells should have a high fusion rate, stable ability of secreting antibodies, be sensitive to HAT culture medium, and the like.
  • the first choice of myeloma cells is murine myeloma, such as MOP-21 and MC-11 mouse tumor derived cell line (THE Salk Institute Cell Distribution Center, San Diego, Calif.
  • human myeloma and human-mouse heterogenous myeloma cell lines may be used to prepare human monoclonal antibodies ( Kozbor, J. Immunol., 133: 3001 (1984 ); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63, Marcel Dekker, Inc., New York, 1987 ). Culture media for growing hybridoma cells are used to detect the generation of monoclonal antibodies against specific antigens.
  • the following methods may be used to determine the binding specificity of monoclonal antibodies produced in hybridoma cells, immunoprecipitation or in vitro binding assays, such as Radioimmunoassay (RIA) and enzyme linked immunosorbent assay (ELISA).
  • RIA Radioimmunoassay
  • ELISA enzyme linked immunosorbent assay
  • Scatchard assay described in Munson et al., Anal. Biochem. 107: 220 (1980 ) may be used to determine the affinity of monoclonal antibodies.
  • cell lines of interest may be subcloned by limiting dilution method described in Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103, Academic Press, 1996 .
  • a suitable culture medium may be DMEM or RPMI-1640, etc.
  • hybridoma cells may grow in a form of ascites tumor in animal bodies.
  • immunoglobulins such as Protein A agarose gel, hydroxyapatite chromatography, gel electrophoresis, dialysis and affinity chromatography, monoclonal antibodies secreted by subclone cells may be isolated from cell culture, ascites or serum.
  • Monoclonal antibodies may be obtained by genetic engineering recombinant techniques.
  • the nucleic acid primers that specifically bind to MAb heavy chain and light chain gene are subjected to PCR amplification, thereby isolating the DNA molecules encoding MAb heavy chain and light chain from hybridoma cells.
  • the DNA molecules obtained are inserted into an expression vector, host cells (e.g. E. coli cells, COS cells, CHO cells, or other myeloma cells that do not produce immunoglobulin) are transfected with them and are cultured under suitable conditions to obtain antibodies of interest by recombinant expression.
  • host cells e.g. E. coli cells, COS cells, CHO cells, or other myeloma cells that do not produce immunoglobulin
  • chimeric antibody refers to such an antibody wherein a part of its light chain and/or heavy chain is derived from an antibody (which may be originated from a specific species or belongs to a specific antibody type or subtype), and the other part of its light chain and/or heavy chain is derived from another antibody (which may be originated from an identical or different species or belongs to an identical or different antibody type or subtype), provided that the antibody still retains the activity of binding to the antigen of interest ( U.S.P 4,816,567 to Cabilly et al. ; Morrison et al., Proc. Natl. Acad. Sci. USA, 81: 6851-6855 (1984 )).
  • humanized antibody refers to an antibody or antibody fragment in which all the CDR regions or a part of CDR regions of human immunoglobulin (receptor antibody) are replaced with the CDR regions of a non-human antibody (donor antibody), wherein the donor antibody may be non-human (e.g., mouse, rat or rabbit) antibody having the expected specificity, affinity or reactivity.
  • donor antibody may be non-human (e.g., mouse, rat or rabbit) antibody having the expected specificity, affinity or reactivity.
  • some amino acids of framework regions (FRs) of a receptor antibody may also be replaced by the corresponding amino acid residues of a non-human antibody, or amino acid residues of another antibody, so as to further improve or optimize the properties of the antibody.
  • neutralization antibody refers to an antibody or antibody fragment that can eliminate or significantly reduce virulence (e.g. ability of infecting cells) of viruses of interest.
  • epitope refers to a portion on antigen that an immunoglobulin or antibody specifically binds to.
  • Epitope is also known as "antigenic determinant”.
  • Epitope or antigenic determinant generally consists of chemically active surface groups of a molecule such as amino acids, carbohydrates or sugar side chains, and generally has a specific three-dimensional structure and a specific charge characteristic.
  • an epitope generally comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive or non-consecutive amino acids in a unique steric conformation, which may be "linear” or “conformational”. See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G. E.
  • epitope peptide refers to peptide fragment on antigen that acts as epitope. Under some conditions, epitope peptide alone can be specifically recognized/bound by an antibody against the epitope. Under some other conditions, epitope peptide has to be fused to a carrier protein to facilitate the epitope to be specifically recognized by an antibody.
  • carrier protein refers to such a protein that may act as a carrier of epitope peptide, i.e.
  • the epitope peptide may be inserted into the protein at a specific position (for example, inner, N-terminal or C-terminal of the protein), so that the epitope peptide can be presented and thus can be recognized by an antibody or immune system.
  • carrier proteins are well known by a person skilled in the art, including, for example, HPV L1 protein (into which the epitope peptide may be inserted between amino acids from positions 130 to 131 or amino acids from positions 426 to 427 of the protein, see Slupetzky, K. et al., Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops [J].
  • HBV core antigen the amino acids from positions 79 to 81 of the protein may be replaced with the epitope peptide, see, Koletzki, D., et al. HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein [J].
  • hepatitis virus core protein the amino acids from positions 79 to 81 of the protein may be replaced with the epitope peptide, see, Sabine König, Gertrud Beterams and Michael Nassal, J. Virol. 1998, 72(6):4997
  • CRM197 protein the epitope peptide may be linked to the N-terminal or C-terminal of the protein or a fragment thereof.
  • a linker e.g., a flexible or rigid linker
  • Antibodies may be screened depending on competitiveness of binding to the same epitope by conventional techniques known by a person skilled in the art. For example, study on competition or cross-competition may be conducted to obtain antibodies that compete or cross-compete with each other for binding to antigens (e.g. influenza virus HA protein). High-throughput methods for obtaining antibodies binding to the same epitope, which are based on their cross-competition, are described in an international patent application WO 03/48731 . Therefore, antibodies and antigen binding fragments (i.e. antigen binding portions) thereof, which compete with monoclonal antibodies according to the invention (e.g. monoclonal antibody 12H5, or G10D10 or 8F11) for binding to the same epitopes on influenza virus HA protein, can be obtained by conventional techniques known by a person skilled in the art.
  • monoclonal antibodies according to the invention e.g. monoclonal antibody 12H5, or G10D10 or 8F11
  • isolated refers to a state obtained from natural state by artificial means. If a certain "isolated” substance or component is present in nature, it is possible because its natural environment changes, or the substance is isolated from natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a certain living animal body, and the same polynucleotide or polypeptide with a high purity isolated from such a natural state is called isolated polynucleotide or polypeptide.
  • isolated excludes neither the mixed artificial or synthesized substance nor other impure substances that do not affect the activity of the isolated substance.
  • E . coli expression system refers to an expression system consisting of E. coli (strain) and a vector, wherein the E. coli (strain) are derived from the commercially available strains, including, but not limited to: GI698, ER2566, BL21 (DE3), B834 (DE3), and BLR (DE3).
  • the term "vector” refers to a nucleic acid vehicle which can have a polynucleotide inserted therein.
  • the vector allows for the expression of the protein encoded by the polynucleotide inserted therein, the vector is called an expression vector.
  • the vector can have the carried genetic material elements expressed in a host cell by transformation, transduction, or transfection into the host cell.
  • Vectors are well known by a person skilled in the art, including, but not limited to plasmids, phages, cosmids, artificial chromosome such as yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC) or P1-derived artificial chromosome (PAC); phage such as ⁇ phage or M13 phage and animal virus.
  • the animal viruses that can be used as vectors include, but are not limited to, retrovirus (including lentivirus), adenovirus, adeno-associated virus, herpes virus (such as herpes simplex virus), pox virus, baculovirus, papillomavirus, papova virus (such as SV40).
  • a vector may comprises multiple elements for controlling expression, including, but not limited to, a promoter sequence, a transcription initiation sequence, an enhancer sequence, a selection element and a reporter gene.
  • a vector may comprise origin of replication.
  • the term "host cell” refers to a cell into which a vector can be introduced, including, but not limited to, prokaryotic cell such as E. coli or Bacillus subtilis, fungal cell such as yeast cell or Aspergillus, insect cell such as S2 Drosophila cell or Sf9, and animal cell such as fibroblast, CHO cell, COS cell, NSO cell, HeLa cell, BHK cell, HEK 293 cell or human cell.
  • prokaryotic cell such as E. coli or Bacillus subtilis
  • fungal cell such as yeast cell or Aspergillus
  • insect cell such as S2 Drosophila cell or Sf9
  • animal cell such as fibroblast, CHO cell, COS cell, NSO cell, HeLa cell, BHK cell, HEK 293 cell or human cell.
  • the term "identity" refers to the match degree between two polypeptides or between two nucleic acids.
  • two sequences for comparison have the same base or amino acid monomer sub-unit at a certain site (e.g., each of two DNA molecules has an adenine at a certain site, or each of two polypeptides has a lysine at a certain site)
  • the two molecules are identical at the site.
  • the percent identity between two sequences is a function of the number of identical sites shared by the two sequences over the total number of sites for comparison x 100. For example, if 6 of 10 sites of two sequences are matched, these two sequences have an identity of 60%.
  • DNA sequences CTGACT and CAGGTT share an identity of 50% (3 of 6 sites are matched).
  • the comparison of two sequences is conducted in a manner to produce maximum identity.
  • Such alignment can be conducted by using a computer program such as Align program (DNAstar, Inc.) which is based on the method of Needleman, et al. (J. Mol. Biol. 48:443-453, 1970 ).
  • the percent identity between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4:11-17 (1988 )) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
  • the percentage of identity between two amino acid sequences can be determined by the algorithm of Needleman and Wunsch (J. Mol. Biol. 48:444-453 (1970 )) which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
  • conservative substitution refers to amino acid substitutions which would not disadvantageously affect or change the essential properties of a protein/polypeptide comprising the amino acid sequence.
  • a conservative substitution may be introduced by standard techniques known in the art such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • Conservative amino acid substitutions include substitutions wherein an amino acid residue is substituted with another amino acid residue having a similar side chain, for example, a residue physically or functionally similar (such as, having similar size, shape, charge, chemical property including the capability of forming covalent bond or hydrogen bond, etc.) to the corresponding amino acid residue.
  • the families of amino acid residues having similar side chains have been defined in the art.
  • amino acids having alkaline side chains for example, lysine, arginine and histidine
  • amino acids having acidic side chains for example, aspartic acid and glutamic acid
  • amino acids having uncharged polar side chains for example, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan
  • amino acids having nonpolar side chains for example, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine
  • amino acids having ⁇ -branched side chains such as threonine, valine, isoleucine
  • amino acids having aromatic side chains for example, tyrosine, phenylalanine, tryptophan, histidine.
  • a corresponding amino acid residue is preferably substituted with another amino acid residue from the same side-chain family.
  • Methods for identifying amino acid conservative substitutions are well known in the art (see, for example, Brummell et al., Biochem. 32: 1180-1187 (1993 ); Kobayashi et al., Protein Eng. 12(10): 879-884 (1999 ); and Burks et al., Proc. Natl. Acad. Sci. USA 94: 412-417 (1997 )).
  • the term "immunogenicity” refers to ability of stimulating the formation of specific antibodies or sensitized lymphocytes in organisms. It not only refers to the property of an antigen to stimulate a specific immunocyte to activate, proliferate and differentiate so as to finally generate immunologic effector substance such as antibody and sensitized lymphocyte, but also refers to the specific immune response that antibody or sensitized T lymphocyte can be formed in immune system of an organism after stimulating the organism with an antigen. Immunogenicity is the most important property of an antigen. Whether an antigen can successfully induce the generation of an immune response in a host depends on three factors, properties of an antigen, reactivity of a host, and immunization means.
  • an antibody that specifically binds to an antigen refers to an antibody that binds to the antigen with an affinity (K D ) of less than about 10 -5 M, e.g. of less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 M or less.
  • K D refers to a dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity of an antibody to an antigen.
  • an antibody binds to an antigen (e.g., influenza virus HA protein) with a K D of less than about 10 -5 M, e.g., less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 M or less, determined by, for example, surface plasmon resonance (SPR) in BIACORE device.
  • an antigen e.g., influenza virus HA protein
  • amino acids are generally represented by single letter codes or three letter codes.
  • alanine may be represented by A or Ala.
  • hybridoma and the term “hybridoma cell line” may be used interchangeably.
  • they also include subclone and progeny cell of hybridoma.
  • hybridoma cell line 12H5, G10D10 or 8F11 when hybridoma cell line 12H5, G10D10 or 8F11 is mentioned, it also refers to the subclone and progeny cell of hybridoma cell line12H5, G10D10 or 8F11.
  • a pharmaceutically acceptable carrier and/or excipient refers to a carrier and/or excipient pharmacologically and/or physiologically compatible with a subject and an active agent, which is well known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995 ), and includes, but is not limited to pH adjuster, surfactant, adjuvant and ionic strength enhancer.
  • the pH adjuster includes, but is not limited to, phosphate buffer;
  • the surfactant includes, but is not limited to, cationic, anionic, or non-ionic surfactant, e.g., Tween-80;
  • the ionic strength enhancer includes, but is not limited to, sodium chloride.
  • adjuvant refers to a non-specific immunopotentiator, which can enhance immune response to an antigen or change the type of immune response in an organism when it is delivered together with the antigen to the organism or is delivered to the organism in advance.
  • adjuvants including, but not limited to, aluminum adjuvants (for example, aluminum hydroxide), Freund's adjuvants (for example, Freund's complete adjuvant and Freund's incomplete adjuvant), coryne bacterium parvum, lipopolysaccharide, cytokines, and the like.
  • Freund's adjuvant is the most commonly used adjuvant in animal experiments now.
  • Aluminum hydroxide adjuvant is more commonly used in clinical trials.
  • protein vaccine refers to a polypeptide-based vaccine, optionally comprising an adjuvant.
  • Polypeptides in vaccines may be obtained by genetic engineering techniques or by methods of chemical synthesis.
  • nucleic acid vaccine refers to a DNA or RNA-based vaccine (such as plasmid, e.g., expression plasmid), optionally comprising an adjuvant.
  • an effective amount refers to an amount that is sufficient to achieve or at least partially achieve the expected effect.
  • an amount effective for preventing a disease refers to an amount effective for preventing, suppressing, or delaying the occurrence of a disease (such as influenza virus infection or diseases associated with influenza virus infection).
  • An effective amount for treating a disease refers to an amount effective for curing or at least partially blocking a disease and its complication in a patient having the disease. The determination of such an effective amount is within the ability of a person skilled in the art.
  • an amount effective for a therapeutic use depends on severity of a disease to be treated, general state of the immune system in a patient, general conditions of a patient, such as age, weight and gender, administration means of drugs, additional therapies used simultaneously, and the like.
  • the inventor surprisingly found by conducting a lot of experimental researches that there were highly conserved epitopes in HA1 domain of surface antigen HA protein of influenza virus H1N1, and antibodies recognizing these epitopes could specifically bind to HA1 domain of different HA subtypes of influenza virus and specifically bind to HA protein of H1 subtype and H5 subtype of influenza viruses, and had a broad-spectrum viral reactivity and ability of neutralizing viruses. Therefore, the antibodies according to the invention are particularly suitable for preventing or treating influenza virus infection or diseases associated with influenza virus infection (e.g., influenza).
  • influenza virus infection e.g., influenza
  • the invention provides a monoclonal antibody and an antigen binding fragment thereof, wherein the monoclonal antibody can specifically bind to HA1 domain of different HA subtypes of influenza virus and specifically bind to HA1 domain (more particularly, epitopes in HA1 domain) of HA protein of H1 subtype (including seasonal H1N1 and 2009 pandemic H1N1) and H5 subtype of influenza viruses.
  • the monoclonal antibody according to the invention has the heavy chain and light chain CDRs selected from the group consisting of
  • the monoclonal antibody according to the invention is derived from or is the following monoclonal antibody: the monoclonal antibody produced by hybridoma cell line 12H5 or G10D10 or 8F11, wherein the hybridoma cell line 12H5, G10D10 and 8F11 are deposited in China Center for Type Culture Collection (CCTCC), and have a deposition number of CCTCC NO: C201230, CCTCC NO: C201229 and CCTCC NO: C2013119, respectively.
  • CTCC China Center for Type Culture Collection
  • the monoclonal antibody or antigen binding fragment thereof according to the invention is selected from Fab, Fab', F(ab') 2 , Fd, Fv, dAb, complementary determining region fragment, single chain antibody (e.g., scFv), mouse antibody, rabbit antibody, humanized antibody, full-human antibody, chimeric antibody (e.g., human mouse chimeric antibody), or bispecific or poly-specific antibody.
  • the monoclonal antibody according to the invention comprises non-CDR region, and the non-CDR region is from species other than murine species, e.g., is from human antibody.
  • the specification discloses a monoclonal antibody and an antigen binding fragment thereof, which can specifically bind to HA1 domain of different HA subtypes of influenza virus and specifically bind to HA1 domain or epitopes comprised therein of HA protein of H1 subtype (including seasonal H1N1 and 2009 pandemic H1N1) and H5 subtype of influenza viruses, wherein the monoclonal antibody can block the binding of the HA1 domain or epitopes comprised therein of the HA protein to a monoclonal antibody selected from the group consisting of:
  • the epitope recognized by such a monoclonal antibody is the same as, or sterically overlaps with, that recognized by the monoclonal antibody 12H5 or G10D10 or 8F11, so that such a monoclonal antibody can reduce the binding of the monoclonal antibody 12H5 or G10D10 or 8F11 to the corresponding epitope by at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95% or preferably at least 99%.
  • the invention also provides an isolated nucleic acid molecule, encoding the monoclonal antibody or antigen binding fragment thereof according to the invention.
  • the nucleic acid molecule can be isolated from a hybridoma cell, or can be obtained by genetic engineering recombinant technique or method of chemical synthesis.
  • the invention provides an isolated nucleic acid molecule, comprising a nucleic acid sequence encoding the heavy chain variable region of the monoclonal antibody according to the invention.
  • the invention provides an isolated nucleic acid molecule, comprising a nucleic acid sequence encoding the light chain variable region of the monoclonal antibody according to the invention.
  • the invention provides a vector comprising the isolated nucleic acid molecule according to the invention.
  • the vector according to the invetion may be a cloning vector, or an expression vector.
  • the vector according to the invention is a plasmid, a cosmid, a phage, etc.
  • the invention also provides a host cell comprising the isolated nucleic acid molecule or vector according to the invention.
  • host cells include, but are not limited to, prokaryotic cell such as E. coli cell, and eukaryotic cell such as yeast cell, insect cell, plant cell and animal cell (such as mammalian cell, e.g., mouse cell, human cell, etc.).
  • the cell according to the invention may be a cell line, such as 293T cell.
  • the invention provides a method for producing the monoclonal antibody or antigen binding fragment thereof according to the invention, comprising culturing the host cell according to the invention under suitable conditions, and recovering the monoclonal antibody or antigen binding fragment thereof according to the invention from the cell culture.
  • the invention provides a hybridoma cell line 12H5, deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO: C201230.
  • the invention provides a hybridoma cell line G10D10, deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO: C201229.
  • the invention provides a hybridoma cell line 8F11, deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO: C2013119.
  • amino acid sequences and/or nucleotide sequences of the heavy chain variable region, the light chain variable region, the heavy chain variable region CDRs and the light chain variable region CDRs can be determined from the monoclonal antibody 12H5, G10D10 and 8F11 by conventional methods.
  • the specification discloses a kit comprising the monoclonal antibody or antigen binding fragment thereof according to the invention.
  • the monoclonal antibody or antigen binding fragment thereof according to the invention may also comprise a detectable marker.
  • the kit may further comprises a second antibody that specifically binds to the monoclonal antibody or antigen binding fragment thereof according to the invention.
  • the second antibody further comprises a detectable marker.
  • detectable markers include, but are not limited to, radioisotope, fluorescent substance, luminescent substance, chromophoric substance and enzyme (e.g., horseradish peroxidase), etc.
  • the invention provides a method for detecting in vitro the presence or level of HA protein of H1 subtype and/or H5 subtype influenza virus in a sample, comprising using the monoclonal antibody or antigen binding fragment thereof according to the invention.
  • the monoclonal antibody or antigen binding fragment thereof according to the invention further comprises a detectable marker.
  • the method further comprises using a second antibody carrying a detectable marker to detect the monoclonal antibody or antigen binding fragment thereof according to the invention.
  • the method may be used for diagnostic purpose or for non-diagnostic purpose (for example, said sample is a cell sample, rather than a sample from a patient).
  • the invention provides a method for diagnosing whether a subject is infected by H1 subtype and/or H5 subtype influenza virus comprising: using the monoclonal antibody or antigen binding fragment thereof according to the invention to detect the presence of H1 subtype and/or H5 subtype influenza virus in a sample derived from the subject.
  • the monoclonal antibody or antigen binding fragment thereof according to the invention further comprises a detectable marker.
  • the method further comprises using a second antibody carrying a detectable marker to detect the monoclonal antibody or antigen binding fragment thereof according to the invention.
  • the specification discloses the use of the monoclonal antibody or antigen binding fragment thereof according to the invention in the manufacture of a kit for detecting the presence or level of HA protein of H1 subtype and/or H5 subtype influenza virus in a sample, or for diagnosing whether a subject is infected by H1 subtype and/or H5 subtype influenza virus.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the monoclonal antibody or antigen binding fragment thereof according to the invention, and a pharmaceutically acceptable carrier and/or excipient.
  • the specification discloses a method for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g., influenza), comprising administering a prophylactically or therapeutically effective amount of the monoclonal antibody or antigen binding fragment thereof according to the invention or the pharmaceutical composition according to the invention to a subject in need thereof.
  • a disease caused by the infection e.g., influenza
  • the specification discloses the use of the monoclonal antibody or antigen binding fragment thereof according to the invention in manufacture of a pharmaceutical composition for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g., influenza).
  • a pharmaceutical composition for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g., influenza).
  • the monoclonal antibody or antigen binding fragment thereof for use in preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g., influenza).
  • the medicament and pharmaceutical composition provided in the invention may be used alone or in combination, or may be used in combination with another pharmaceutically active agent (e.g., interferon agents, such as interferon or pegylated interferon).
  • another pharmaceutically active agent e.g., interferon agents, such as interferon or pegylated interferon.
  • hybridoma cell lines 12H5 and G10D10 according to invention were deposited in China Center for Type Culture Collection (CCTCC, Wuhan University, Wuhan, China) on Feb. 20, 2012, with a deposition number of CCTCC NO: C201230 and CCTCC NO: C201229, respectively.
  • Hybridoma cell line SH1-8F11 of the invention (also called hybridoma cell line 8F11 for short in the context), was deposited in China Center for Type Culture Collection (CCTCC, Wuhan University, Wuhan, China) on Sep. 05, 2013, with a deposition number of CCTCC NO: C2013119.
  • Example 1 Preparation of a monoclonal antibody (mAb) against HA of H1 subtype influenza virus
  • MDCK cells were inoculated with three seasonal H1N1 influenza virus strains (i.e. A/New Calidonia/20/1999 (H1N1), A/Xiamen/3118/2006 (H1N1), and A/Xiamen/N585/2009 (H1N1)) and a 2009 pandemic H1N1 influenza virus strain A/California/04/2009 (H1N1), respectively.
  • H1N1 influenza virus strains i.e. A/New Calidonia/20/1999 (H1N1), A/Xiamen/3118/2006 (H1N1), and A/Xiamen/N585/2009 (H1N1)
  • H1N1 influenza virus strains i.e. A/New Calidonia/20/1999 (H1N1), A/Xiamen/3118/2006 (H1N1), and A/Xiamen/N585/2009 (H1N1)
  • the inactivated viruses were subjected to HA detection to determine the titer of the inactivated viruses (Note: please refer to WHO Operation Guideline for methods of HA titer determination and HI detection; A/California/04/2009 was given as a gift by Department of Microorganism, University of Hongkong; A/New Calidonia/20/1999, A/Xiamen/3118/2006, A/Xiamen/N585/2009 were the viral strains preserved in the inventor's laboratory).
  • Monoclonal antibodies were obtained by standard in vivo immunization method and PEG fusion method; please refer to Ed Harlow et al., "Antibodies A Laboratory Manual", Cold Spring Harbor Laboratory 1988 for detail. The brief process was as followed.
  • the titers of the inactivated viruses were adjusted to a low dose of 8HA for immunization.
  • the virus A/New Calidonia/20/1999(H1N1) was mixed and emulsified with an equal volume of Freund's complete adjuvant (CFA), and then was administered to limbs of mice by multi-point intramuscular injection, at an amount of 400ul for each mouse.
  • CFA Freund's complete adjuvant
  • the viruses A/Xiamen/3118/2006 (H1N1) and A/Xiamen/N585/2009 (H1N1) were separately used in combination with incomplete Freund's adjuvant (IFA) for booster immunization at 14d and 28d.
  • IFA incomplete Freund's adjuvant
  • the final booster immunization was carried out to spleens of mice at 42d.
  • the immunogen was a solution of said viruses mixed with an equal volume, 100ul for each mouse. 3d later, spleens of the mice were taken for fusion experiment.
  • the spleen was ground to obtain a suspension of spleen cells, and then was mixed with mouse myeloma cells SP2/0 in exponential growth phase.
  • Cell fusion was carried out in the presence of PEG1500.
  • the fused cells were re-suspended in 400 ml fusion culture medium, and then were subpackaged to 20 96-well plates for culture.
  • the fusion culture medium was a RPMI1640 complete screening culture medium containing HAT and 20% FBS.
  • Antigenic broad-spectrum clones were screened by ELISA and neutralization assay. After cloning for three times, stable cell lines were obtained.
  • the cell supernatant was taken for Hemagglutination-Inhibition (HI) test.
  • the virus for detection was A/New Calidonia/20/1999(H1N1), and the positive wells were used for cloning until the antibodies secreted by the cell line were able to stably inhibit the agglutination of virus and red blood cell.
  • 25 stable hybridoma cell lines were firstly subjected to amplification culture in a CO 2 incubator, and then were transferred from a 96-well plate to a 24-well plate, and later to a 50 ml cell bottle for amplification culture.
  • the cells collected from the cell bottle were injected to peritoneal cavities of mice. 7-10d later, ascites were drawn from the peritoneal cavities of mice.
  • the ascites were precipitated with 50% ammonium sulfate.
  • the precipitate was dissolved in PBS, and then purified through Protein A column in AKTA system to get the purified monoclonal antibodies.
  • the purity of the purified monoclonal antibodies was identified by SDS-PAGE.
  • Example 2 Evaluation of broad-spectrum reactivity of broad-spectrum monoclonal antibodies against HA of H1/H5 subtype by HI assay
  • HI assay was used to determine the cross-reactivity of the mAb ascites of said 25 monoclonal antibodies with different H subtype of influenza viruses, and three broad-spectrum monoclonal antibodies 12H5, G10D10 and 8F11, which could recognize H1 and H5 subtype of influenza viruses simultaneously, were identified (Table 1).
  • the monoclonal antibody 12H5 could react with seasonal H1 subtype influenza virus, 2009 pandemic H1N1 influenza A virus and H5 subtype avian influenza virus simultaneously, and showed a good broad-spectrum reactivity with different HA subtypes of influenza virus.
  • the monoclonal antibodies G10D10 and 8F11 could react with seasonal H1 subtype influenza virus and H5 subtype avian influenza virus simultaneously, but not with 2009 pandemic H1N1 influenza A virus.
  • the monoclonal antibodies G10D10 and 8F11 had a broader reactive spectrum than 12H5 in the case of seasonal H1 subtype influenza virus, could react with both H1 virus isolated in 1930s and H1 virus newly isolated after 2008, had a broader reactive spectrum than 12H5 in the case of H5 subtype avian influenza virus, and could react with more H5N1 virus strains.
  • the results showed that the monoclonal antibodies G10D10 and 8F11 were also good monoclonal antibodies having broad-spectrum reactivity with different HA subtypes of influenza virus.
  • Table 1 Activity of broad-spectrum monoclonal antibody against HA of H1/H5 subtype in HI assay (HI titer) Subtype Virus HI titer of mAbs 12H5 G10D10 8F11 Seasonal H1N1 A/WSN/1933 ⁇ 100 400 6400 A/PR/8/1934 ⁇ 100 400 800 A/Texas/36/1991 6400 ⁇ 12800 ⁇ 12800 A/HK/134801/1994 ⁇ 12800 ⁇ 12800 3200 A/Beijing/262/1995 6400 ⁇ 12800 ⁇ 12800 A/New Calidonia/20/1999 ⁇ 12800 ⁇ 12800 6400 A/Shantou/104/2005 ⁇ 12800 ⁇ 12800 ⁇ 12800 A/Xiamen/3115/2006 ⁇ 12800 ⁇ 12800 ⁇ 12800 A/Xiamen/1128/2006 ⁇ 12800 ⁇ 12800 ⁇ 12800 A/Solomon Islands/3/2006 800 ⁇ 12800 6400 A/Brisban
  • Example 3 Evaluation of the broad-spectrum neutralizing activity (Neutralizion titer) of broad-spectrum monoclonal antibodies against HA of H1/H5 subtype by microwell neutralization assay
  • Neutralization activity is an important index for assessing whether a monoclonal antibody has therapeutic potential.
  • Microwell neutralization assay was used to determine the neutralization activity of the monoclonal antibodies 12H5, G10D10 and 8F11 for representative strains of H1N1 and H5N1 subtype influenza viruses ( Hulse-Post et al., PNAS. 2005, 102: 10682-7 ).
  • the results (Table 2) showed that the results of neutralization assay were substantively consistent with the results of HI assay, and the three monoclonal antibodies (12H5, G10D10 and 8F11) had broad-spectrum cross-neutralizing activity with H1N1 and H5N1 viruses.
  • Table 2 Activity of broad-spectrum monoclonal antibodies against HA of H1/H5 subtype in neutralization assay Virus subtype/clade Neutralizing titer 12H5 G10D10 8F11 A/H K/13480 1/1994 seasonal H1N1 12800 12800 12800 A/New Calidonia/20/1999 seasonal H1N1 12800 12800 12800 A/Brisbane/59/2007 seasonal H1N1 3200 12800 12800 A/California/07/2009 2009 pandemic H1N1 1600 ⁇ 100 ⁇ 100 A/Xiamen/N514/2009 2009 pandemic H1N1 1600 ⁇ 100 ⁇ 100 A/HK/MB-1/2010 2009 pandemic H1N1 12800 ⁇ 100 ⁇ 100 A/HK/402618/2011 2009 pandemic H1N1 3200 ⁇ 100 ⁇ 100 A/Viet Nam/1194/2004 H5N1 (clade 1) 3200 6400 12800 A/BHGs/Qinghai/15
  • Example 4 Evaluation of broad-spectrum monoclonal antibody against HA of H1/H5 subtype by blocking-capturing PCR method
  • broad-spectrum monoclonal antibody was assayed by blocking-capturing PCR method. The method was as followed.
  • Blocking-capturing PCR method and Quantity One software were used to analyze and determine the blocking rate of PBS, 12H5, G10D10 and 13A12 to block the capture of H1 influenza virus NC20 by monoclonal antibody 12H5, respectively.
  • the results ( Figure 1A ) showed that H1 monoclonal antibodies 12H5 and G10D10 could well block the capture of NC20 virus by the monoclonal antibody 12H5, while neither of the unrelated monoclonal antibody 13A12 and PBS control could block the capture of NC20 by the monoclonal antibody 12H5.
  • Example 5 The epitope recognized by broad-spectrum monoclonal antibodies against HA of H1/H5 subtype was determined as within HA1 domain by analyzing escape mutation.
  • the monoclonal antibodies 12H5, G10D10 and 8F11 were used to induce and screen escape mutants.
  • the positive escape virus thus obtained was purified and subjected to amplification culture, and its gene was obtained, sequenced and was analyzed for the escape mutation site, so as to determine the region in which the epitope recognized by the monoclonal antibodies 12H5, G10D10 and 8F11 was present.
  • Parent virus seasonal H1N1 virus A/Brisbane/59/2007 and 2009 pandemic H1N1 virus A/California/07/2009 were selected as parent viruses for escape mutation screening.
  • Monoclonal antibodies 12H5, G10D10 and 8F11 Escape screening: 10 5 TCID50 virus was mixed with a monoclonal antibody, and the final concentration of monoclonal antibody was 1mg/ml, with a total volume of 1ml. After incubating at room temperature for 4 hours, the virus-monoclonal antibody complex was used for infecting the MDCK cells pre-plated on a 96-well plate.
  • the mixture was taken, and a maintenance medium containing 50ug/ml monoclonal antibody was added, and the cells were cultured at 37°C for 48 h.
  • the culture supernatant was determined by hemagglutination test, the positive virus wells were cloned. After cloning for three times, stable escape viral strains were obtained. Localization of escape mutation sites: the obtained escape mutant virus was subjected to RT-PCR for amplification of the structural gene of the virus, and the structural gene thus obtained was sequenced and was aligned with the structural gene of the parent virus to obtain the escape mutation sites.
  • escape mutation screening results for the monoclonal antibody 12H5 showed that the escape mutation sites involved the amino acid residues at position 138, 142 and 186 (H3 numbering, the same below) of HA1 gene.
  • 5 escape strains were obtained by A/Brisbane/59/2007 (H1N1)-based virus escape screening, and all had mutation at position 142 of HA (N142D);
  • 19 escape strains were obtained by A/California/07/2009 (2009 pandemic H1N1)-based virus escape screening, among which 1 had mutation at position 138 of HA (A138S), 8 had mutation at position 142 of HA (A142E), and the remaining 10 had mutation at position 186 of HA (S186P).
  • Table 3 The amino acid mutation sites of HA from the monoclonal antibody 12H5-induced escape strains H1N1 parent virus escape mutation site in HA a A/Brisbane/59/2007 N142D(5/5) A/California/07/2009 A138S(1/19) A 142E(8/19) S186P(10/19)
  • the escape mutation screening result for the monoclonal antibody G10D10 (Table 4) showed that the escape mutation site involved the amino acid residue at position 142 of HA1 gene.
  • 4 escape strains were obtained by A/Brisbane/59/2007 (H1N1)-based virus escape screening, and all had mutation at position 142 (N142H for two strains, N142S for one strain and N142Y for one strain).
  • Table 4 The amino acid mutation sites of HA from the monoclonal antibody G10D10-induced escape strains H1N1 parent virus escape mutation site in HA a A/Brisbane/59/2007 N142H(2/4) N142S(1/4) N142Y(1/4)
  • the escape mutation screening result for the monoclonal antibody 8F11 (Table 5) showed that the escape mutation site involved the amino acid residue at position 142 of HA1 gene.
  • 5 escape strains were obtained by A/Brisbane/59/2007 (H1N1)-based virus escape screening, and all had mutation at position 142 (N142D for 4 strains, and N142K for one strain).
  • Table 5 The amino acid mutation sites of HA from the monoclonal antibody 8F11-induced escape strains H1N1 escape parent virus escape mutation site in HA a A/Brisbane/59/2007 N142 D (4/5) N142K(1/5)
  • the escape mutation results showed that the monoclonal antibodies 12H5, G10D10, and 8F11 recognized similar epitopes, and the epitopes they recognized were all present in HA1 domain of influenza virus HA protein, and all of them recognized the amino acid at position 142 of HA.
  • Example 6 Separation of light chain gene and heavy chain gene of monoclonal antibodies against HA of H1/H5 subtype
  • the supernatant liquid was transferred to a new 1.5ml centrifuge tube, and an equal volume of isopropanol was added, mixed, standing for 10min, and then centrifuged at 4°C, 12000rpm for 10min. The supernatant was removed, 600 ⁇ l of 75% ethanol was added for washing, and then centrifuged at 4°C, 12000rpm for 5min. The supernatant was removed, and the precipitate was dried under vacuum at 60°C for 5 min. The transparent precipitate was dissolved in 70ul DEPC H 2 O, and was subpackaged into two tubes.
  • reverse transcription primer 5'-CCG TTT GKA TYT CCA GCT TGG TSC C-3'
  • MVDJhR 5'-CGG TGA CCG WGG TBC CTT GRC CCC A-3'
  • the gene of the variable region of the antibody was isolated by polymerase chain reaction (PCR) method.
  • the primer set synthesized according to Ig-Prime kits of Novagen Company and another two designed and synthesized downstream primers MVJkR, MVDJhR (synthesized by ShangHai Boya Company) were used, wherein MVJkR was a downstream primer for amplification of the gene of light variable region, and MVDJhR was a downstream primer for amplification of the gene of heavy variable region.
  • the templates were the two cDNA as synthesized above. PCR conditions were: 94°C 5min; (94°C 40s, 53°C 1min, 72°C 50s) x 35 cycles ; 72°C 15min.
  • fragments of interest were recovered and were cloned to pMD 18-T vector, and then were sent to ShangHai Boya Company for sequencing. By blast alignment, the sequences of antibody variable regions were determined, and the corresponding amino acid sequences were determined.
  • the genes of the antibody variable regions were cloned from the hybridoma cell lines secreting broad-spectrum monoclonal antibodies 12H5, G10D10 and 8F11, and the corresponding amino acid sequences were determined.
  • Table 6 showed the sequences of the upstream primers used, and Table 7 showed the amino acid sequences of antibody variable regions, and the complementary determinant regions (CDRs) were determined by Kabat method ( Kabat EA, Wu TT, Perry HM, Gottesman KS, Coeller K. Sequences of proteins of immunological interest, U.S Department of Health and Human Services, PHS, NIH, Bethesda, 1991 ).
  • upstream primers for amplification of variable region genes of the broad-spectrum monoclonal antibodies 12H5, G10D10, and 8F11 Variable region gene of mAb Name of upstream primer Sequence of upstream primer 12H5Vh MulgVh5'-D1 (SEQ ID NO: 21) 5'-ATGGRCAGRCTTACWTYYTCATTCCT-3' 12H5Vk MulgkVl5'-E1 (SEQ ID NO: 22) 5'-ATGTGGGGAYCGKTTTYAMMCTTTTCAATTG-3' G10D10Vh MulgVh5'-C2 (SEQ ID NO: 23) 5'-ATGGVTTGGSTGTGGAMCTTGCYATTCCT-3' G10D10Vk MulgkVl5'-B (SEQ ID NO: 24) 5'-ATGGAGACAGACACACTCCTGCTAT-3' 8F11Vh MulgVh5'-C2 (SEQ ID NO: 25) 5'-At
  • Example 7 Application of broad-spectrum monoclonal antibodies against HA of H1/H5 subtype for detection of influenza virus
  • MDCK cells were infected by representative strains of seasonal H1 subtype influenza virus (A/New Calidonia/20/1999 and A/Brisbane/59/2007), a representative strain of 2009 pandemic H1N1 influenza A virus (A/California/04/2009), and a representative strain of seasonal H3 subtype influenza virus (A/Brisbane/59/2007(H3N2)) as control.
  • the cells were fixed 24h after infection.
  • Immunofluorescence assay was used to analyze the effect of monoclonal antibodies 12H5 and G10D10 for detection of influenza virus.
  • the results ( Figure 2 ) showed that the monoclonal antibody 12H5 had good reactivity with the HA antigens of the two classes of H1 subtype influenza viruses, wherein the fluorescence was mainly observed on cell membrane, and was also observed in cytoplasm.
  • the monoclonal antibody 12H5 had no specific reactivity with H3 subtype influenza virus and negative cells.
  • the monoclonal antibody G10D10 had good reactivity with the HA antigens of the seasonal H1N1 influenza virus, but had no specific reactivity with the 2009 pandemic H1N1 influenza A virus and H3 subtype influenza virus ( Figure 3 ).
  • the results were consistent with the results of HI test and the neutralization assay, indicating that they are useful for detecting influenza virus in cells.
  • Example 8 Application of broad-spectrum monoclonal antibodies against HA of H1/H5 subtype for treatment of influenza virus infection
  • mice Balb/C mice, SPF, 6-8 week old, female, weighted about 20g.
  • mice were sent to ABSL-3 laboratory one day ahead, and were divided into 4 groups, with 5 mice per cage, designated as G1, G2, ising etc.; the weight of each mouse was recorded, the regimens were shown in Table 8.
  • H5 virus QH15C was pre-diluted to 10 3 TCID 50 / ⁇ l
  • H1 viruses RP8 and CA04-MA were pre-diluted to 10 5 TCID 50 / ⁇ l
  • the mice were inoculated with the virus at 25 ⁇ l/mouse. Before inoculation, mice were anesthetized with isoflorane, and then infected by inoculation of virus via nasal cavity.
  • MAb intervention 24h (dpi.1) after virus infection, the mice in antibody-treatment group were injected with antibody at different doses, i.e. 20mg/kg, 10mg/kg, 5mg/kg and 2.5mg/kg, respectively, wherein the injection volume was100 ⁇ l/mouse.
  • mice 12H5 treatment regimen G1 Blank control group PBS PBS 5 G2 H1 virus control group CA07-MA PBS 5 G3 H1 treatment group 1 CA07-MA 12H5 10mg/kg 5 G4 H1 treatment group 2 CA07-MA 12H5 5mg/kg 5 G5 H1 treatment group 3 CA07-MA 12H5 2.5mg/kg 5 G6 H5 virus control group QH15C PBS 5 G7 H5 treatment group 1 QH15C 12H5 10mg/kg 5 G8 H5 treatment group 2 QH15C 12H5 5mg/kg 5 G9 H5 treatment group 3 QH15C 12H5 2.5mg/kg 5 G10D10 treatment regimen G10 Blank control group PBS PBS 5 G11 H1 virus control group PR8 PBS 5 G12 H
  • mice were separately infected by CA7 virus of 2009 pandemic H1N1 and H5N1 virus strain QH15C at a one-week lethal dose. Antibody intervention was initiated 1 day after infection. The treatment effect of monoclonal antibody was determined by measuring the body weight and calculating the survival rate ( Figure 4 ). It could be seen that no significant weight fluctuation was observed in negative control group during the experiment; significant weight loss was observed in two virus control groups, all the mice died 6 days after infection in CA07 virus control group, and all the mice died 9 days after infection in QH15C virus control group. In the case of said two viruses, 12H5 antibody intervention at different doses leaded to weight recovery in mice ( Figures 4A and 4C ).
  • mice were separately infected by H5N1 virus strain QH15C and seasonal influenza virus strain PR8 (recent seasonal H1N1 virus was not pathogenic to mice, and therefore early H1N1 virus strain PR8 pathogenic to mice was used in this experiment) at a one-week lethal dose, and used for evaluating the treatment effect of the monoclonal antibody G10D10. Since the monoclonal antibody G10D10 had a weak activity for PR8 (HI titer was only 400), a high dose (20mg/kg) was used in the animal experiment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Description

    Technical Field
  • The invention relates to the field of molecular virology, particularly the field concerning vaccines for the prevention of influenza virus. In particular, the invention relates to antibodies recognizing epitopes on HA1 domain of hemagglutinin of influenza virus, cell lines for producing the antibodies, and uses thereof. The antibodies according to the invention can specifically bind to HA1 domain of different HA subtypes of Influenza virus and specifically bind to HA1 domain of hemagglutinin (HA) protein of H1 subtype (including seasonal H1N1 and 2009 pandemic H1N1) and H5 subtype of influenza viruses. Therefore, the invention also discloses vaccines or pharmaceutical compositions for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or diseases caused by the infection (e.g. influenza), comprising the antibodies according to the invention.
    • Background Art
  • Influenza, commonly known as "the flu", is a respiratory infectious disease caused by the influenza virus, and has the symptoms of high fever, feeling tired, and muscle pains, accompanied by some respiratory symptoms. Influenza virus is a threat to human health, the sustained and rapid antigenic drift cause wide spread of seasonal influenza. According to statistics of WHO, seasonal influenza is responsible for the death of at least 250,000-500,000 persons per year (Peter D.C. et al., J Clin Invest. 2008, 118:3273-3275). In addition, flu outbreak is still an important threat to human beings. Since influenza virus was discovered, flu outbreak occured five times around world in human history, resulting in tens of millions of deaths; among them, Spanish influenza (H1N1) in 1918 resulted in about 20-50 millions of deaths in the world. The inflenza pandemics occurred in the 20th century also include Asian influenza (H2N2) in 1957 and Hong Kong Influenza (H3N2) in 1968, both of which caused serious public health threat and human social panic (Xu R. et al., Science. 2010, 328: 357-360). In the 21st century, influenza outbreaks still do not stop; influenza A (2009 pandemic H1N1) outbreak occurred in Mexico in 2009 and quickly spreaded around the world, which sounded the alarm to human society once again; according to WHO statistics, up to August 6, 2010, a total of 18,449 cases of confirmed deaths were reported in more than 200 countries and regions globally (WHO Pandemic (H1N1) 2009 - update 112. 6 Aug, 2010). In addition, human beings also face the threat of highly pathogenic avian influenza, and highly pathogenic H5N1 avian influenza virus has become one of the greatest infectious diseases that threats human beings, after "SARS" in 2003. Since 2003, 600 cases of human infected by avian influenza virus H5N1 are reported globally, among which 353 cases died, with a mortality rate close to 60% (WHO: http://www.who.int/influenza/human_ animal_interface/H5N1_cumulative_table_archives/en/index.html). Due to such a high mortality rate, people can not help but worry that once the virus spreads in human, it will bring a fatal blow to human society.
  • Influenza virus is an enveloped, single stranded, negative-sense RNA virus that belongs to the genus influenza virus of the family Orthomyxoviridae. Its genome contains eight segments of RNA, and encode for more than 10 viral proteins. According to the difference in antigenicity and genetic characteristics of nucleoprotein (NP) and matrix protein (M), influenza virus can be classified into Influenza virus A, Influenza virus B, and Influenza virus C (Horimoto T. et al., Nat Rev Microbiol, 2005, 3(8): 591-600). Influenza A Virus (called Flu A for short) mutates fast, has a strong pathogenicity, and can cause worldwide pandemics. Influenza B Virus (called Flu B for short) mutates slow and can only cause small pandemics in local areas. Influenza C Virus (called Flu C for short) mutates slowest, has a weak pathogenicity, and can only infect pregnant women and children with a low resistance generally. In nature, there are a broad range of hosts for Flu A. Flu A can cause infection in animals such as human, horses and pigs, in addition to its natural host aquatic birds. Flu A has multiple subtypes which are different from each other greatly, and has become a research focus for influenza control and vaccine.
  • Flu A viruses are categorized into subtypes based on the antigenicity and genetic characteristics of the two surface antigens, i.e. hemagglutinin (HA) and neuraminidase (NA). There are 17 known HA subtypes (H1 to H17) and 10 known NA subtypes (N1 to N10) (Tong S.X. et al., PNAS. 2012, 109(11):4269-74). The Flu A subtypes epidemic in human beings include two HA subtypes (H1, H3) and two NA subtypes (N1, N2). Although highly pathogenic avian influenza virus H5N1 only infects human beings occasionally, it draws attention due to the high mortality rate.
  • The first line of defense to prevent influenza is neutralizing antibodies. The vaccine-induced neutralizing antibodies mainly target the membrane protein hemagglutinin (HA) on the surface of virus. HA protein on the surface of virus has a trimeric structure, and each HA monomer consists of HA1 domain and HA2 domain. HA1 forms a globule at the top of the trimer, contains receptor binding sites, and is a region essential for the virus to infect a host cell; HA1 also contains important antigenic sites, can induce generation of protective neutralizing antibodies in organisms, and thus is a key target for vaccine design (Wang T.T. et al., Nat Struct Mol Biol. 2009, 16: 233-234). HA2 is located at the base of the trimer, has a shape of stem, contains fusion peptide, and can mediate the fusion of viral envelope to host cell membrane; and some monoclonal antibodies against HA2 can inhibit the membrane fusion of influenza virus so as to achieve the effect of neutralizing virus (Wang T.T. et al., Nat Struct Mol Biol. 2009, 16: 233-234).
  • Influenza viruses have a high variability, particularly, HA mutates fastest. In current, traditional influenza vaccines are mainly directed to HA protein, and the influenza vaccines become ineffective easily because of virus antigenic drift caused by HA gene mutation. In order to keep influenza vaccines effective, WHO annually needs to monitor the mutation of the influenza virus strains epidemic last year, and select old influenza virus vaccines or establish new influenza virus vaccines as candidate influenza vaccines next year so as to retain the effective protection from epidemic influenza virus strains by inoculation of new vaccines every year. Therefore, development of "universal influenza vaccines" that are not affected by virus mutation becomes a research focus for development of new vaccines. The glycoprotein on the surface of influenza virus, i.e. "hemagglutinin (HA)", is a main target for the development of universal influenza vaccines and immunotherapeutic medicines against influenza virus. The so-called "universal influenza vaccines" should comprise "highly conserved neutralizing epitopes" shared by different viral mutants, and can directly induce the generalization of "broad-spectrum neutralizing antibodies" to combat the infection by different virus mutants. Therefore, an important route for studying universal influenza vaccines and immunotherapeutic medicines against influenza is to look for highly conserved neutralizing epitopes on HA.
  • In addition, in a mouse animal model, a humanized HA monoclonal antibody specific to H1N1 and H5N1 has been demonstrated to be able to effectively treat experimental mice infected by influenza virus (Corti D. et al., J Clin Invest. 2010,120:1663-1673). In clinic, polyclonal antibodies and monoclonal antibodies can be effectively applied to the prevention of infections by viruses such as Hepatitis A Virus, Hepatitis B Virus, rabies virus and respiratory syncytial virus (Sawyer L.A. et al., Antiviral Res. 2000, 47: 57-77). During Spanish influenza in 1918, it was reported that serum from human in convalescent stage was used for the treatment (Luke T.C. et al., Ann Intern Med. 2006, 145:599-609). The information suggests that antibodies can be used as alternative methods and tools for anti-viral therapy.
  • Antibodies for preventing or treating influenza infection have been described (see for example WO2010/010467 , US2012/058124 , WO2012/045001 , and WO2013/030604 ).
  • HA broad-spectrum monoclonal antibodies and highly conserved epitopes have been reported in many papers. Studies on broad-spectrum monoclonal antibodies and highly conserved epitopes against HA2 which is more conservative have become a major research focus (Throsby M. et al., PLoS One. 2009, 3: e3942; Sui J. et al., Nat Struct Mol Biol. 2009, 16: 265-273; Corti D. et al., J Clin Invest. 2010, 120: 1663-1673; Corti D. et al., Science. 2011, 333: 850-856). As early as 2009, Throsby et al. reported for the first time that a broad-spectrum neutralizing humanized monoclonal antibody CR6261 recognizing HA2 could neutralize all the influenza viruses belonging to Group 1 (including H1, H2, H5, H6, H8 and H9 subtypes) (Throsby M. et al., PLoS One. 2009, 3: e3942). In 2011, Corti D. et al. also obtained a humanized broad-spectrum neutralizing monoclonal antibody against HA2 by similar technology, which could neutralize 16 types of H subtype influenza viruses (Corti D. et al., Science. 2011, 333: 850-856), and became one of the most broad-spectrum neutralizing monoclonal antibodies against influenza reported recently. The discovery of these broad-spectrum monoclonal antibodies provides new hope for the development of broad-spectrum therapeutic monoclonal antibodies and universal influenza vaccines against influenza virus. The epitopes recognized by the monoclonal antibodies obtained in said studies are all located in a conservative region surrounding the fusion peptide on HA2, the main function of which is to mediate the membrane fusion of influenza virus, and the monoclonal antibodies do not recognize HA1 domain that have immune predominance. Therefore, it increases the uncertainty in the prospect of applying these antibodies and the recognized conservative epitopes to the treatment and prevention. Some studies show that the neutralizing monoclonal antibodies recognizing HA2 have a neutralizing activity reduced by 100-1000 folds for natural virus, as compared to pseudovirus, which may be due to the fact that the HA2 epitope of natural virus is not easily exposed and is difficult to be approached (Sui J. et al., Nat Struct Mol Biol. 2009, 16: 265-273; Corti D. et al., J Clin Invest. 2010, 120: 1663-1673).
  • As compared to HA2, HA1 of influenza virus forms a globule at the top of the trimer, contains a lot of neutralizing epitopes, and is easily accessible. Therefore, it is more possible to develop effective universal influenza vaccines and therapeutic antibodies by looking for highly conserved neutralizing epitopes on HA1. Since the subtypes of influenza virus are divided initially based on serotyping of polyclconal antibodies and the pAb serum against one subtype has little cross-reactivity with virus of another subtype, it is generally believed that the neutralizing monoclonal antibodies specific to HA (particularly HA1) are serotype-specific and has no cross-reactivity with HA of another subtype. However, it is also found in some researches recently that the highly conserved neutralizing epitopes on HA1 can induce the generation of broad-spectrum monoclonal antibodies having cross-subtypes reactivity (Yoshida R. et al., PLoS Pathog. 2009, 5: e1000350; Krause J.C. et al., J Virol. 2011, 85: 10905-10908; Wrammert J. et al., J Exp Med. 2011, 208: 181-193). Since HA1 has a high variability, the reactive spectrum of the current HA1 monoclonal antibodies is narrow, as compared to that of HA2 monoclonal antibodies, and the HA1 monoclonal antibodies generally have a cross-neutralizing activity for 2-3 subtypes of influenza viruses. Yoshida et al. reported in 2008 that a HA1 broad-spectrum neutralizing monoclonal antibody, S139/1, could neutralize H1, H2, H3 and H13 subtypes of influenza viruses, but the neutralizing activity of the monoclonal antibody was only limited to a few virus strains for each of said subtypes (Yoshida R. et al., PLoS Pathog. 2009, 5: e1000350). After the 2009 pandemic H1N1 outbreak in 2009, many papers reported cross-neutralizing monoclonal antibodies against 2009 pandemic H1N1 and seasonal H1N1 influenza viruses, including the cross-neutralizing monoclonal antibody against 2009 pandemic H1N1 and H1N1 of 1918 (Krause J.C. et al., J Virol. 2010, 84: 3127-3130; Xu K. et al., Viral Immunol. 2011, 24: 45-56), and the cross-neutralizing monoclonal antibody against 2009 pandemic H1N1 and seasonal H1N1 epidemic recently (Krause J.C. et al., J Virol. 2011, 85: 10905-10908; Wrammert J. et al., J Exp Med. 2011, 208: 181-193). In addition, when screening a broad-spectrum neutralizing monoclonal antibody against HA2, Corti et al. also obtained a cross-neutralizing monoclonal antibody FE17 against HA1, which could cross-neutralize seasonal H1 and H5 subtypes of influenza viruses, and the epitope of which was located close to Ca2 antigenic region. These studies show that HA1 may contain conservative neutralizing epitopes, which are important for the research on universal influenza vaccines and immunotherapeutic medicines. Therefore, it is of importance and instructiveness for the development of broad-spectrum therapeutic antibodies and universal influenza vaccines against influenza, to look for broad-spectrum neutralizing monoclonal antibodies that recognize more highly conserved neutralizing epitopes on HA1 and to accurately localize the epitopes.
    • Contents of Invention The invention is defined by the claims.
  • In the invention, unless otherwise specified, the scientific and technical terms used herein have the meanings as generally understood by a person skilled in the art. Moreover, the laboratory operations of cell culture, molecular genetics, nucleic acid chemistry and immunology used herein are the routine operations widely used in the corresponding fields. Meanwhile, in order to better understand the invention, the definitions and explanations of the relevant terms are provided as follows.
  • As used herein, the term "H3 numbering" refers to the numbering based on the amino acid sequence of the HA obtained by aligning the HA amino acid sequence of H1N1 virus with the amino acid sequence of HA (with the signal peptide removed) of H3N2 virus strain A/Hong Kong/1/1968 (H3N2) (Genbank: AAK51718.1). Therefore, as used herein, the amino acid residue at position N (such as position 142) of HA refers to the amino acid residue corresponding to the one at position N (such as position 142) of the amino acid sequence of the aligned HA.
  • As used herein, the term "antibody" generally refers to an immunoglobulin molecule consisting of two pairs of polypeptide chains (each has a light (L) chain and a heavy (H) chain). Light chains of an antibody may be classified into κ and λ light chain. Heavy chains may be classified into µ, δ, γ, α and ε, which define isotypes of an antibody as IgM, IgD, IgG, IgA and IgE, respectively. In a light chain and a heavy chain, a variable region is linked to a constant region via a "J" region of about 12 or more amino acids, and a heavy chain further comprises a "D" region of about 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). A heavy chain constant region consists of 3 domains (C H1, C H2 and CH3). Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). A light chain constant region consists of a domain CL. The constant region of an antibody can mediate the binding of an immunoglobulin to a host tissue or factor, including various cells (e.g., effector cells) of an immune system and the first component (C1q) of classical complement system. VH and VL region can also be divided into hypervariable regions (called complementary determining regions (CDR)), which are interspaced by relatively conservative regions (called framework region (FR)). Each VH and VL consists of 3 CDRs and 4 FRs in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from N-terminal to C-terminal. The variable region (VH and VL) of each heavy/light chain pair forms an antigen binding site, respectively. Distribution of amino acids in various regions or domains follows the definition in Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al., (1989) Nature 342:878-883. The term "antibody" is not restricted by any specific method for producing antibodies. For example, antibodies include particularly, recombinant antibodies, monoclonal antibodies and polyclonal antibodies. Antibodies may be of different antibody isotypes, for example, IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM antibody.
  • As used herein, the term "antigen binding fragment" of an antibody refers to polypeptides comprising fragments of a full-length antibody, which retain the ability of specifically binding to an antigen that the full-length antibody specifically binds to, and/or compete with the full-length antibody for binding to the same antigen, also known as "antigen binding portion". Generally, see Fundamental Immunology, Ch. 7 (Paul, W., ed., the second edition, Raven Press, N.Y. (1989). Antigen binding fragments of an antibody may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of an intact antibody. Under some conditions, antigen binding fragments include Fab, Fab', F(ab')2, Fd, Fv, dAb and complementary determining region (CDR) fragments, single chain antibody (e.g. scFv), chimeric antibody, diabody and such polypeptides that comprise at least a part of an antibody sufficient to confer the ability of specific binding with the antigen to the polypeptides.
  • As used herein, the term "Fd fragment" refers to an antibody fragment consisting of VH and C H1 domain; the term "Fv fragment" refers to an antibody fragment consisting of VL and VH domain of a single arm; the term "dAb fragment" refers to an antibody fragment consisting of VH domain (Ward et al., Nature 341:544-546 (1989)); the term "Fab fragment" refers to an antibody fragment consisting of VL, VH, CL and C H1 domain; the term "F(ab')2 fragment" refers to an antibody fragment comprising two Fab fragments linked to each other via disulphide bridge(s) on hinge region.
  • Under some conditions, antigen binding fragments of an antibody are single chain antibodies (e.g. scFv), wherein VL and VH domain are paired to form a monovalent molecule via a linker that enables them to produce a single polypeptide chain (see, for example, Bird et al., Science 242:423-426 (1988) and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988)). Such scFv molecules generally have a common structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Suitable linkers in the prior art consist of repeated GGGGS amino acid sequence or variants thereof. For example, a linker having an amino acid sequence (GGGGS)4 may be used, and its variants may also be used (Holliger et al., (1993), Proc. Natl. Acad. Sci. USA 90: 6444-6448). Other linkers that may be used in the invention are described by Alfthan et al., (1995), Protein Eng. 8:725-731, Choi et al., (2001), Eur. J. Immunol. 31: 94-106, Hu et al., (1996), Cancer Res. 56:3055-3061, Kipriyanov et al., (1999), J. Mol. Biol. 293:41-56 and Roovers et al., (2001), Cancer Immunol.
  • Under some conditions, antigen binding fragments of an antibody may be diabodies, i.e. divalent antibodies, wherein VH and VL domain are expressed on a single polypeptide chain, however, the linker used is too short to allow the pairing of the two domains on the same chain, the domains have to be paired with the complementary domains on another chain to produce two antigen binding sites (see, for example, Holliger P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993), and Poljak R. J. et al., Structure 2:1121-1123 (1994)).
  • Antigen binding fragments (e.g. the antibody fragments as described above) of an antibody may be obtained from a given antibody (e.g., the monoclonal antibody provided in the invention) by conventional techniques known by a person skilled in the art (e.g., recombinant DNA technique or enzymatic or chemical cleavage methods), and may be screened for specificity in the same manner by which intact antibodies are screened.
  • In the invention, unless specified definitely, when the term "antibody" is mentioned, it includes not only intact antibodies, but also antigen binding fragments of the antibodies.
  • As used herein, the term "mAb" and "monoclonal antibody" refer to an antibody or a fragment of an antibody from a population of highly homologous antibody molecules, i.e. a population of completely identical antibody molecules except for natural mutation that may occur spontaneously. A monoclonal antibody has a high specificity for a single epitope of an antigen. Polyclonal antibody, relative to monoclonal antibody, generally comprises at least two or more different antibodies which generally recognize different epitopes on an antigen. Monoclonal antibodies are generally obtained by hybridoma technique reported by Kohler et al. for the first time (Nature, 256:495, 1975), and can also be obtained by recombinant DNA technique (see, for example, U.S.P 4,816,567 ).
  • For example, monoclonal antibodies may be prepared as follows. Firstly, mice or other suitable host animals are immunized by injection of immunogen (if necessary, adjuvants are added). The injection means of immunogens or adjuvants generally are subcutaneous multi-point injection or intraperitoneal injection. Pre-conjugation of immunogens to some known proteins (e.g. serum albumin or soybean trypsin inhibitor) may promote immunogenicity of antigens in a host. Adjuvants may be Freund's adjuvant or MPL-TDM, etc. After immunization of animal, lymphocytes secreting antibodies that specifically bind to immunogen are produced in the animal. In addition, lymphocytes may be obtained by means of in vitro immunization. Lymphocytes of interest are collected and are fused to myeloma cells using a suitable fusion agent (such as PEG), thereby getting hybridoma cells (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103, Academic Press, 1996). The hybridoma cells prepared above are seeded to a suitable culture medium and grow in the medium, and the culture medium comprises one or more substances capable of inhibiting growth of unfused, parent myeloma cells. For example, in the case of parent myeloma cells deficient in hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), growth of HGPRT-deficient cells is inhibited by the addition of substances such as hypoxanthine, aminopterin and thymine (HAT culture medium) to the culture medium. Preferred myeloma cells should have a high fusion rate, stable ability of secreting antibodies, be sensitive to HAT culture medium, and the like. The first choice of myeloma cells is murine myeloma, such as MOP-21 and MC-11 mouse tumor derived cell line (THE Salk Institute Cell Distribution Center, San Diego, Calif. USA), and SP-2/0 or X63-Ag8-653 cell line (American Type Culture Collection, Rockville, Md. USA). In addition, human myeloma and human-mouse heterogenous myeloma cell lines may be used to prepare human monoclonal antibodies (Kozbor, J. Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63, Marcel Dekker, Inc., New York, 1987). Culture media for growing hybridoma cells are used to detect the generation of monoclonal antibodies against specific antigens. The following methods may be used to determine the binding specificity of monoclonal antibodies produced in hybridoma cells, immunoprecipitation or in vitro binding assays, such as Radioimmunoassay (RIA) and enzyme linked immunosorbent assay (ELISA). For example, Scatchard assay described in Munson et al., Anal. Biochem. 107: 220 (1980) may be used to determine the affinity of monoclonal antibodies. After determining the specifcity, affinity and reactivity of antibodies produced in hybridomas, cell lines of interest may be subcloned by limiting dilution method described in Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103, Academic Press, 1996. A suitable culture medium may be DMEM or RPMI-1640, etc. In addition, hybridoma cells may grow in a form of ascites tumor in animal bodies. By using traditional methods for purifying immunoglobulins, such as Protein A agarose gel, hydroxyapatite chromatography, gel electrophoresis, dialysis and affinity chromatography, monoclonal antibodies secreted by subclone cells may be isolated from cell culture, ascites or serum.
  • Monoclonal antibodies may be obtained by genetic engineering recombinant techniques. The nucleic acid primers that specifically bind to MAb heavy chain and light chain gene are subjected to PCR amplification, thereby isolating the DNA molecules encoding MAb heavy chain and light chain from hybridoma cells. The DNA molecules obtained are inserted into an expression vector, host cells (e.g. E. coli cells, COS cells, CHO cells, or other myeloma cells that do not produce immunoglobulin) are transfected with them and are cultured under suitable conditions to obtain antibodies of interest by recombinant expression.
  • As used herein, the term "chimeric antibody" refers to such an antibody wherein a part of its light chain and/or heavy chain is derived from an antibody (which may be originated from a specific species or belongs to a specific antibody type or subtype), and the other part of its light chain and/or heavy chain is derived from another antibody (which may be originated from an identical or different species or belongs to an identical or different antibody type or subtype), provided that the antibody still retains the activity of binding to the antigen of interest ( U.S.P 4,816,567 to Cabilly et al. ; Morrison et al., Proc. Natl. Acad. Sci. USA, 81: 6851-6855 (1984)).
  • As used herein, the term "humanized antibody" refers to an antibody or antibody fragment in which all the CDR regions or a part of CDR regions of human immunoglobulin (receptor antibody) are replaced with the CDR regions of a non-human antibody (donor antibody), wherein the donor antibody may be non-human (e.g., mouse, rat or rabbit) antibody having the expected specificity, affinity or reactivity. In addition, some amino acids of framework regions (FRs) of a receptor antibody may also be replaced by the corresponding amino acid residues of a non-human antibody, or amino acid residues of another antibody, so as to further improve or optimize the properties of the antibody. With respect to more detailed contents relating to humanized antibodies, see, for example, Jones et al., Nature, 321:522-525 (1986); Reichmann et al., Nature, 332:323-329 (1988); Presta, Curr. Op. Struct. Biol., 2:593-596 (1992); and Clark, Immunol. Today 21: 397-402 (2000).
  • As used herein, the term "neutralization antibody" refers to an antibody or antibody fragment that can eliminate or significantly reduce virulence (e.g. ability of infecting cells) of viruses of interest.
  • As used herein, the term "epitope" refers to a portion on antigen that an immunoglobulin or antibody specifically binds to. "Epitope" is also known as "antigenic determinant". Epitope or antigenic determinant generally consists of chemically active surface groups of a molecule such as amino acids, carbohydrates or sugar side chains, and generally has a specific three-dimensional structure and a specific charge characteristic. For example, an epitope generally comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive or non-consecutive amino acids in a unique steric conformation, which may be "linear" or "conformational". See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G. E. Morris, Ed. (1996). In a linear epitope, all the interaction sites between a protein and an interaction molecule (e.g., an antibody) are present linearly along the primary amino acid sequence of the protein. In a conformational epitope, the interaction sites span over amino acid residues that are separate from each other in a protein.
  • As used herein, the term "epitope peptide" refers to peptide fragment on antigen that acts as epitope. Under some conditions, epitope peptide alone can be specifically recognized/bound by an antibody against the epitope. Under some other conditions, epitope peptide has to be fused to a carrier protein to facilitate the epitope to be specifically recognized by an antibody. As used herein, the term "carrier protein" refers to such a protein that may act as a carrier of epitope peptide, i.e. the epitope peptide may be inserted into the protein at a specific position (for example, inner, N-terminal or C-terminal of the protein), so that the epitope peptide can be presented and thus can be recognized by an antibody or immune system. Such carrier proteins are well known by a person skilled in the art, including, for example, HPV L1 protein (into which the epitope peptide may be inserted between amino acids from positions 130 to 131 or amino acids from positions 426 to 427 of the protein, see Slupetzky, K. et al., Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops [J]. J Gen Virol, 2001, 82: 2799-2804 ; Varsani, A. et al., Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16 [J]. J Virol, 2003, 77: 8386-8393), HBV core antigen (the amino acids from positions 79 to 81 of the protein may be replaced with the epitope peptide, see, Koletzki, D., et al. HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein [J]. Biol Chem, 1999, 380: 325-333), woodchuck hepatitis virus core protein (the amino acids from positions 79 to 81 of the protein may be replaced with the epitope peptide, see, Sabine König, Gertrud Beterams and Michael Nassal, J. Virol. 1998, 72(6):4997), and CRM197 protein (the epitope peptide may be linked to the N-terminal or C-terminal of the protein or a fragment thereof). Optionally, a linker (e.g., a flexible or rigid linker) may be used between an epitope peptide and a carrier protein to promote their folding, respectively.
  • Antibodies may be screened depending on competitiveness of binding to the same epitope by conventional techniques known by a person skilled in the art. For example, study on competition or cross-competition may be conducted to obtain antibodies that compete or cross-compete with each other for binding to antigens (e.g. influenza virus HA protein). High-throughput methods for obtaining antibodies binding to the same epitope, which are based on their cross-competition, are described in an international patent application WO 03/48731 . Therefore, antibodies and antigen binding fragments (i.e. antigen binding portions) thereof, which compete with monoclonal antibodies according to the invention (e.g. monoclonal antibody 12H5, or G10D10 or 8F11) for binding to the same epitopes on influenza virus HA protein, can be obtained by conventional techniques known by a person skilled in the art.
  • As used herein, the term "isolated" refers to a state obtained from natural state by artificial means. If a certain "isolated" substance or component is present in nature, it is possible because its natural environment changes, or the substance is isolated from natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a certain living animal body, and the same polynucleotide or polypeptide with a high purity isolated from such a natural state is called isolated polynucleotide or polypeptide. The term "isolated" excludes neither the mixed artificial or synthesized substance nor other impure substances that do not affect the activity of the isolated substance.
  • As used herein, the term "E. coli expression system" refers to an expression system consisting of E. coli (strain) and a vector, wherein the E. coli (strain) are derived from the commercially available strains, including, but not limited to: GI698, ER2566, BL21 (DE3), B834 (DE3), and BLR (DE3).
  • As used herein, the term "vector" refers to a nucleic acid vehicle which can have a polynucleotide inserted therein. When the vector allows for the expression of the protein encoded by the polynucleotide inserted therein, the vector is called an expression vector. The vector can have the carried genetic material elements expressed in a host cell by transformation, transduction, or transfection into the host cell. Vectors are well known by a person skilled in the art, including, but not limited to plasmids, phages, cosmids, artificial chromosome such as yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC) or P1-derived artificial chromosome (PAC); phage such as λ phage or M13 phage and animal virus. The animal viruses that can be used as vectors, include, but are not limited to, retrovirus (including lentivirus), adenovirus, adeno-associated virus, herpes virus (such as herpes simplex virus), pox virus, baculovirus, papillomavirus, papova virus (such as SV40). A vector may comprises multiple elements for controlling expression, including, but not limited to, a promoter sequence, a transcription initiation sequence, an enhancer sequence, a selection element and a reporter gene. In addition, a vector may comprise origin of replication.
  • As used herein, the term "host cell" refers to a cell into which a vector can be introduced, including, but not limited to, prokaryotic cell such as E. coli or Bacillus subtilis, fungal cell such as yeast cell or Aspergillus, insect cell such as S2 Drosophila cell or Sf9, and animal cell such as fibroblast, CHO cell, COS cell, NSO cell, HeLa cell, BHK cell, HEK 293 cell or human cell.
  • As used herein, the term "identity" refers to the match degree between two polypeptides or between two nucleic acids. When two sequences for comparison have the same base or amino acid monomer sub-unit at a certain site (e.g., each of two DNA molecules has an adenine at a certain site, or each of two polypeptides has a lysine at a certain site), the two molecules are identical at the site. The percent identity between two sequences is a function of the number of identical sites shared by the two sequences over the total number of sites for comparison x 100. For example, if 6 of 10 sites of two sequences are matched, these two sequences have an identity of 60%. For example, DNA sequences: CTGACT and CAGGTT share an identity of 50% (3 of 6 sites are matched). Generally, the comparison of two sequences is conducted in a manner to produce maximum identity. Such alignment can be conducted by using a computer program such as Align program (DNAstar, Inc.) which is based on the method of Needleman, et al. (J. Mol. Biol. 48:443-453, 1970). The percent identity between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4:11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percentage of identity between two amino acid sequences can be determined by the algorithm of Needleman and Wunsch (J. Mol. Biol. 48:444-453 (1970)) which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
  • As used herein, the term "conservative substitution" refers to amino acid substitutions which would not disadvantageously affect or change the essential properties of a protein/polypeptide comprising the amino acid sequence. For example, a conservative substitution may be introduced by standard techniques known in the art such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions include substitutions wherein an amino acid residue is substituted with another amino acid residue having a similar side chain, for example, a residue physically or functionally similar (such as, having similar size, shape, charge, chemical property including the capability of forming covalent bond or hydrogen bond, etc.) to the corresponding amino acid residue. The families of amino acid residues having similar side chains have been defined in the art. These families include amino acids having alkaline side chains (for example, lysine, arginine and histidine), amino acids having acidic side chains (for example, aspartic acid and glutamic acid), amino acids having uncharged polar side chains (for example, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), amino acids having nonpolar side chains (for example, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), amino acids having β-branched side chains (such as threonine, valine, isoleucine) and amino acids having aromatic side chains (for example, tyrosine, phenylalanine, tryptophan, histidine). Therefore, a corresponding amino acid residue is preferably substituted with another amino acid residue from the same side-chain family. Methods for identifying amino acid conservative substitutions are well known in the art (see, for example, Brummell et al., Biochem. 32: 1180-1187 (1993); Kobayashi et al., Protein Eng. 12(10): 879-884 (1999); and Burks et al., Proc. Natl. Acad. Sci. USA 94: 412-417 (1997)).
  • As used herein, the term "immunogenicity" refers to ability of stimulating the formation of specific antibodies or sensitized lymphocytes in organisms. It not only refers to the property of an antigen to stimulate a specific immunocyte to activate, proliferate and differentiate so as to finally generate immunologic effector substance such as antibody and sensitized lymphocyte, but also refers to the specific immune response that antibody or sensitized T lymphocyte can be formed in immune system of an organism after stimulating the organism with an antigen. Immunogenicity is the most important property of an antigen. Whether an antigen can successfully induce the generation of an immune response in a host depends on three factors, properties of an antigen, reactivity of a host, and immunization means.
  • As used herein, the term "specifically bind" refers to the binding of two molecules in a non-random manner, such as the reaction between an antibody and the antigen it directs to. In some embodiments, an antibody that specifically binds to an antigen (or an antibody specific for an antigen) refers to an antibody that binds to the antigen with an affinity (KD) of less than about 10-5 M, e.g. of less than about 10-6 M, 10-7 M, 10-8 M, 10-9 M or 10-10 M or less.
  • As used herein, the term "KD" refers to a dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity of an antibody to an antigen. The smaller the dissociation equilibrium constant is, the more closely the antibody binds to the antigen and the higher the affinity of the antibody to the antigen is. Generally, an antibody (e.g., the monoclonal antibody 12H5, G10D10 or 8F11 according to the invention) binds to an antigen (e.g., influenza virus HA protein) with a KD of less than about 10-5 M, e.g., less than about 10-6 M, 10-7 M, 10-8 M, 10-9 M or 10-10 M or less, determined by, for example, surface plasmon resonance (SPR) in BIACORE device.
  • As used herein, the term "monoclonal antibody" and the term "MAb" have the same meanings and are used interchangeably; the term "polyclonal antibody" and the term "PAb" have the same meanings and are used interchangeably; the term "polypeptide" and "protein" have the same meanings and are used interchangeably. Moreover, in the invention, amino acids are generally represented by single letter codes or three letter codes. For example, alanine may be represented by A or Ala.
  • As used herein, the term "hybridoma" and the term "hybridoma cell line" may be used interchangeably. When the term "hybridoma" and the term "hybridoma cell line" are mentioned, they also include subclone and progeny cell of hybridoma. For example, when hybridoma cell line 12H5, G10D10 or 8F11 is mentioned, it also refers to the subclone and progeny cell of hybridoma cell line12H5, G10D10 or 8F11.
  • As used herein, the term "a pharmaceutically acceptable carrier and/or excipient" refers to a carrier and/or excipient pharmacologically and/or physiologically compatible with a subject and an active agent, which is well known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to pH adjuster, surfactant, adjuvant and ionic strength enhancer. For example, the pH adjuster includes, but is not limited to, phosphate buffer; the surfactant includes, but is not limited to, cationic, anionic, or non-ionic surfactant, e.g., Tween-80; the ionic strength enhancer includes, but is not limited to, sodium chloride.
  • As used herein, the term "adjuvant" refers to a non-specific immunopotentiator, which can enhance immune response to an antigen or change the type of immune response in an organism when it is delivered together with the antigen to the organism or is delivered to the organism in advance. There are a variety of adjuvants, including, but not limited to, aluminum adjuvants (for example, aluminum hydroxide), Freund's adjuvants (for example, Freund's complete adjuvant and Freund's incomplete adjuvant), coryne bacterium parvum, lipopolysaccharide, cytokines, and the like. Freund's adjuvant is the most commonly used adjuvant in animal experiments now. Aluminum hydroxide adjuvant is more commonly used in clinical trials.
  • As used herein, the term "protein vaccine" refers to a polypeptide-based vaccine, optionally comprising an adjuvant. Polypeptides in vaccines may be obtained by genetic engineering techniques or by methods of chemical synthesis. As used herein, the term "nucleic acid vaccine" refers to a DNA or RNA-based vaccine (such as plasmid, e.g., expression plasmid), optionally comprising an adjuvant.
  • As used herein, the term "an effective amount" refers to an amount that is sufficient to achieve or at least partially achieve the expected effect. For example, an amount effective for preventing a disease (such as influenza virus infection or diseases associated with influenza virus infection) refers to an amount effective for preventing, suppressing, or delaying the occurrence of a disease (such as influenza virus infection or diseases associated with influenza virus infection). An effective amount for treating a disease refers to an amount effective for curing or at least partially blocking a disease and its complication in a patient having the disease. The determination of such an effective amount is within the ability of a person skilled in the art. For example, an amount effective for a therapeutic use depends on severity of a disease to be treated, general state of the immune system in a patient, general conditions of a patient, such as age, weight and gender, administration means of drugs, additional therapies used simultaneously, and the like.
  • The inventor surprisingly found by conducting a lot of experimental researches that there were highly conserved epitopes in HA1 domain of surface antigen HA protein of influenza virus H1N1, and antibodies recognizing these epitopes could specifically bind to HA1 domain of different HA subtypes of influenza virus and specifically bind to HA protein of H1 subtype and H5 subtype of influenza viruses, and had a broad-spectrum viral reactivity and ability of neutralizing viruses. Therefore, the antibodies according to the invention are particularly suitable for preventing or treating influenza virus infection or diseases associated with influenza virus infection (e.g., influenza).
  • Therefore, in one aspect, the invention provides a monoclonal antibody and an antigen binding fragment thereof, wherein the monoclonal antibody can specifically bind to HA1 domain of different HA subtypes of influenza virus and specifically bind to HA1 domain (more particularly, epitopes in HA1 domain) of HA protein of H1 subtype (including seasonal H1N1 and 2009 pandemic H1N1) and H5 subtype of influenza viruses.
  • The monoclonal antibody according to the invention has the heavy chain and light chain CDRs selected from the group consisting of
    1. 1) the heavy chain CDR1-3 set forth in SEQ ID NOs: 1-3, and the light chain CDR1-3 set forth in SEQ ID NOs: 4-6;
    2. 2) the heavy chain CDR1-3 set forth in SEQ ID NOs: 7-9, and the light chain CDR1-3 set forth in SEQ ID NO: 10-12; and
    3. 3) the heavy chain CDR1-3 set forth in SEQ ID NOs: 13-15, and the light chain CDR1-3 set forth in SEQ ID NO: 16-18.
  • In a preferred embodiment, the monoclonal antibody according to the invention is derived from or is the following monoclonal antibody: the monoclonal antibody produced by hybridoma cell line 12H5 or G10D10 or 8F11, wherein the hybridoma cell line 12H5, G10D10 and 8F11 are deposited in China Center for Type Culture Collection (CCTCC), and have a deposition number of CCTCC NO: C201230, CCTCC NO: C201229 and CCTCC NO: C2013119, respectively.
  • In a preferred embodiment, the monoclonal antibody or antigen binding fragment thereof according to the invention is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementary determining region fragment, single chain antibody (e.g., scFv), mouse antibody, rabbit antibody, humanized antibody, full-human antibody, chimeric antibody (e.g., human mouse chimeric antibody), or bispecific or poly-specific antibody.
  • In a preferred embodiment, the monoclonal antibody according to the invention comprises non-CDR region, and the non-CDR region is from species other than murine species, e.g., is from human antibody.
  • In one aspect, the specification discloses a monoclonal antibody and an antigen binding fragment thereof, which can specifically bind to HA1 domain of different HA subtypes of influenza virus and specifically bind to HA1 domain or epitopes comprised therein of HA protein of H1 subtype (including seasonal H1N1 and 2009 pandemic H1N1) and H5 subtype of influenza viruses, wherein the monoclonal antibody can block the binding of the HA1 domain or epitopes comprised therein of the HA protein to a monoclonal antibody selected from the group consisting of:
    1. 1) a monoclonal antibody produced by a hybridoma cell line 12H5 with a deposition number of CCTCC NO: C201230;
    2. 2) a monoclonal antibody produced by a hybridoma cell line G10D10 with a deposition number of CCTCC NO: C201229; and
    3. 3) a monoclonal antibody produced by a hybridoma cell line 8F11 with a deposition number of CCTCC NO: C2013119,
    by at least 50%, preferably at least 70%, more preferably at least 90%, e.g., at least 95%, at least 96%, at least 97%, at least 98% or at least 99%.
  • The epitope recognized by such a monoclonal antibody is the same as, or sterically overlaps with, that recognized by the monoclonal antibody 12H5 or G10D10 or 8F11, so that such a monoclonal antibody can reduce the binding of the monoclonal antibody 12H5 or G10D10 or 8F11 to the corresponding epitope by at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95% or preferably at least 99%.
  • The invention also provides an isolated nucleic acid molecule, encoding the monoclonal antibody or antigen binding fragment thereof according to the invention. The nucleic acid molecule can be isolated from a hybridoma cell, or can be obtained by genetic engineering recombinant technique or method of chemical synthesis.
  • In one aspect, the invention provides an isolated nucleic acid molecule, comprising a nucleic acid sequence encoding the heavy chain variable region of the monoclonal antibody according to the invention.
  • In another aspect, the invention provides an isolated nucleic acid molecule, comprising a nucleic acid sequence encoding the light chain variable region of the monoclonal antibody according to the invention.
  • In another aspect, the invention provides a vector comprising the isolated nucleic acid molecule according to the invention. The vector according to the invetion may be a cloning vector, or an expression vector.
  • In a preferred embodiment, the vector according to the invention is a plasmid, a cosmid, a phage, etc.
  • In another aspect, the invention also provides a host cell comprising the isolated nucleic acid molecule or vector according to the invention. Such host cells include, but are not limited to, prokaryotic cell such as E. coli cell, and eukaryotic cell such as yeast cell, insect cell, plant cell and animal cell (such as mammalian cell, e.g., mouse cell, human cell, etc.). The cell according to the invention may be a cell line, such as 293T cell.
  • In another aspect, the invention provides a method for producing the monoclonal antibody or antigen binding fragment thereof according to the invention, comprising culturing the host cell according to the invention under suitable conditions, and recovering the monoclonal antibody or antigen binding fragment thereof according to the invention from the cell culture.
  • In another aspect, the invention provides a hybridoma cell line 12H5, deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO: C201230. In another aspect, the invention provides a hybridoma cell line G10D10, deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO: C201229. In another aspect, the invention provides a hybridoma cell line 8F11, deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO: C2013119.
  • The amino acid sequences and/or nucleotide sequences of the heavy chain variable region, the light chain variable region, the heavy chain variable region CDRs and the light chain variable region CDRs can be determined from the monoclonal antibody 12H5, G10D10 and 8F11 by conventional methods.
  • In another aspect, the specification discloses a kit comprising the monoclonal antibody or antigen binding fragment thereof according to the invention. In a preferred embodiment, the monoclonal antibody or antigen binding fragment thereof according to the invention may also comprise a detectable marker. The kit may further comprises a second antibody that specifically binds to the monoclonal antibody or antigen binding fragment thereof according to the invention. Preferably, the second antibody further comprises a detectable marker. Such detectable markers, which are well known by a person skilled in the art, include, but are not limited to, radioisotope, fluorescent substance, luminescent substance, chromophoric substance and enzyme (e.g., horseradish peroxidase), etc.
  • In another aspect, the invention provides a method for detecting in vitro the presence or level of HA protein of H1 subtype and/or H5 subtype influenza virus in a sample, comprising using the monoclonal antibody or antigen binding fragment thereof according to the invention. In one preferred embodiment, the monoclonal antibody or antigen binding fragment thereof according to the invention further comprises a detectable marker. In another preferred embodiment, the method further comprises using a second antibody carrying a detectable marker to detect the monoclonal antibody or antigen binding fragment thereof according to the invention. The method may be used for diagnostic purpose or for non-diagnostic purpose (for example, said sample is a cell sample, rather than a sample from a patient).
  • In another aspect, the invention provides a method for diagnosing whether a subject is infected by H1 subtype and/or H5 subtype influenza virus comprising: using the monoclonal antibody or antigen binding fragment thereof according to the invention to detect the presence of H1 subtype and/or H5 subtype influenza virus in a sample derived from the subject. In a preferred embodiment, the monoclonal antibody or antigen binding fragment thereof according to the invention further comprises a detectable marker. In another preferred embodiment, the method further comprises using a second antibody carrying a detectable marker to detect the monoclonal antibody or antigen binding fragment thereof according to the invention.
  • In another aspect, the specification discloses the use of the monoclonal antibody or antigen binding fragment thereof according to the invention in the manufacture of a kit for detecting the presence or level of HA protein of H1 subtype and/or H5 subtype influenza virus in a sample, or for diagnosing whether a subject is infected by H1 subtype and/or H5 subtype influenza virus.
  • In another aspect, the invention provides a pharmaceutical composition comprising the monoclonal antibody or antigen binding fragment thereof according to the invention, and a pharmaceutically acceptable carrier and/or excipient.
  • In another aspect, the specification discloses a method for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g., influenza), comprising administering a prophylactically or therapeutically effective amount of the monoclonal antibody or antigen binding fragment thereof according to the invention or the pharmaceutical composition according to the invention to a subject in need thereof.
  • In another aspect, the specification discloses the use of the monoclonal antibody or antigen binding fragment thereof according to the invention in manufacture of a pharmaceutical composition for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g., influenza).
  • In another aspect, provided is the monoclonal antibody or antigen binding fragment thereof according to the invention, for use in preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g., influenza).
  • The medicament and pharmaceutical composition provided in the invention may be used alone or in combination, or may be used in combination with another pharmaceutically active agent (e.g., interferon agents, such as interferon or pegylated interferon).
  • The embodiments of the invention are described in detail by reference to the drawings and examples. However, a person skilled in the art would understand that the following drawings and examples are intended for illustrating the invention only, rather than defining the scope of the invention. According to the detailed description of the following drawings and preferred embodiments, various purposes and advantages of the invention are apparent for a person skilled in the art.
    • Description of the drawings
    • Figure 1A shows the result of agarose gel electrophoresis, indicating the effect of different samples blocking the monoclonal antibody 12H5 to capture NC20 virus; Lane 1, PBS; Lane 2, 12H5; Lane 3, G10D10; Lane 4, anti-FluB monoclonal antibody 13A12; Lane 5, a control sample free of viral gene; Lane 6, DNA2000 Marker.
    • Figure 1B shows the result of agarose gel electrophoresis, indicating the effect of different samples blocking the monoclonal antibody G10D10 to capture NC20 virus; Lane 1, DNA2000 Marker; Lane 2, PBS; Lane 3, 12H5; Lane 4, G10D10; Lane 5, anti-FluB monoclonal antibody 13A12; lane 6, a control sample free of viral gene.
    • Figure 2 shows the effect of the monoclonal antibody 12H5 for the detection of influenza virus antigen in cells.
    • Figure 3 shows the effect of the monoclonal antibody G10D10 for the detection of influenza virus antigen in cells.
    • Figure 4 shows the protective effect of the monoclonal antibody 12H5 for the treatment of mice infected by influenza virus.
    • Figure 5 shows the protective effect of the monoclonal antibody G10D10 for the treatment of mice infected by influenza virus.
    Description of deposition of biological materials
  • The hybridoma cell lines 12H5 and G10D10 according to invention were deposited in China Center for Type Culture Collection (CCTCC, Wuhan University, Wuhan, China) on Feb. 20, 2012, with a deposition number of CCTCC NO: C201230 and CCTCC NO: C201229, respectively.
  • Hybridoma cell line SH1-8F11 of the invention (also called hybridoma cell line 8F11 for short in the context), was deposited in China Center for Type Culture Collection (CCTCC, Wuhan University, Wuhan, China) on Sep. 05, 2013, with a deposition number of CCTCC NO: C2013119.
    • Specific modes for carrying out the invention
  • The present invention is illustrated by reference to the following examples (which are not intended to limit the protection scope of the present invention).
  • Unless indicated otherwise, the molecular biological experimental methods and immunological assays used in the present invention are carried out substantially in accordance with the methods as described in Sambrook J et al., Molecular Cloning: A Laboratory Manual (Second Edition), Cold Spring Harbor Laboratory Press, 1989, and F. M. Ausubel et al., Short Protocols in Molecular Biology, 3rd Edition, John Wiley & Sons, Inc., 1995; restriction enzymes are used under the conditions recommended by manufacturers of the products. When the conditions are not specified in the Examples, the experiments are carried out according to the conventional conditions or the conditions recommended by the manufacturers. The reagents or devices used in the present invention, the manufacturers of which are not indicated, are conventional products in the art that are commercially available. Those skilled in the art understand that the examples are used for illustrating the present invention, but not intended to limit the protection scope of the present invention.
    • Example 1: Preparation of a monoclonal antibody (mAb) against HA of H1 subtype influenza virus (1) Preparation of virus:
  • MDCK cells were inoculated with three seasonal H1N1 influenza virus strains (i.e. A/New Calidonia/20/1999 (H1N1), A/Xiamen/3118/2006 (H1N1), and A/Xiamen/N585/2009 (H1N1)) and a 2009 pandemic H1N1 influenza virus strain A/California/04/2009 (H1N1), respectively. After incubating the cells at 37°C for 2 days, the supernatant was collected to get the amplified viruses. Live viruses were collected, and were inactivated with 0.03% formalin at 4°C. The inactivated viruses were subjected to HA detection to determine the titer of the inactivated viruses (Note: please refer to WHO Operation Guideline for methods of HA titer determination and HI detection; A/California/04/2009 was given as a gift by Department of Microorganism, University of Hongkong; A/New Calidonia/20/1999, A/Xiamen/3118/2006, A/Xiamen/N585/2009 were the viral strains preserved in the inventor's laboratory).
    • (2) Experimental mice:
  • 6-week old female Balb/C mice were provided by Experimental Animal Center, School of Life Sciences, Xiamen University.
    • (3) Preparation of hybridoma:
  • Monoclonal antibodies were obtained by standard in vivo immunization method and PEG fusion method; please refer to Ed Harlow et al., "Antibodies A Laboratory Manual", Cold Spring Harbor Laboratory 1988 for detail. The brief process was as followed.
    • (4) Immunization of mice:
  • The titers of the inactivated viruses were adjusted to a low dose of 8HA for immunization. Firstly, the virus A/New Calidonia/20/1999(H1N1) was mixed and emulsified with an equal volume of Freund's complete adjuvant (CFA), and then was administered to limbs of mice by multi-point intramuscular injection, at an amount of 400ul for each mouse. After primary immunization, the viruses A/Xiamen/3118/2006 (H1N1) and A/Xiamen/N585/2009 (H1N1) were separately used in combination with incomplete Freund's adjuvant (IFA) for booster immunization at 14d and 28d. The final booster immunization was carried out to spleens of mice at 42d. The immunogen was a solution of said viruses mixed with an equal volume, 100ul for each mouse. 3d later, spleens of the mice were taken for fusion experiment.
    • (5) Cell fusion:
  • Firstly, the spleen was ground to obtain a suspension of spleen cells, and then was mixed with mouse myeloma cells SP2/0 in exponential growth phase. Cell fusion was carried out in the presence of PEG1500. The fused cells were re-suspended in 400 ml fusion culture medium, and then were subpackaged to 20 96-well plates for culture. The fusion culture medium was a RPMI1640 complete screening culture medium containing HAT and 20% FBS. Antigenic broad-spectrum clones were screened by ELISA and neutralization assay. After cloning for three times, stable cell lines were obtained.
    • (6) Screening of hybridoma:
  • After culturing the fused cells in the 96-well plates for 10 days, the cell supernatant was taken for Hemagglutination-Inhibition (HI) test. The virus for detection was A/New Calidonia/20/1999(H1N1), and the positive wells were used for cloning until the antibodies secreted by the cell line were able to stably inhibit the agglutination of virus and red blood cell.
    • (7) Screening result of hybridomas secreting monoclonal antibodies:
  • 25 anti-H1 hemagglutinin monoclonal antibodies including 12H5 were obtained.
    • (8) Culture of hybridoma:
  • 25 stable hybridoma cell lines were firstly subjected to amplification culture in a CO2 incubator, and then were transferred from a 96-well plate to a 24-well plate, and later to a 50 ml cell bottle for amplification culture. The cells collected from the cell bottle were injected to peritoneal cavities of mice. 7-10d later, ascites were drawn from the peritoneal cavities of mice.
    • (9) Purification of monoclonal antibody:
  • The ascites were precipitated with 50% ammonium sulfate. The precipitate was dissolved in PBS, and then purified through Protein A column in AKTA system to get the purified monoclonal antibodies. The purity of the purified monoclonal antibodies was identified by SDS-PAGE.
    • Example 2: Evaluation of broad-spectrum reactivity of broad-spectrum monoclonal antibodies against HA of H1/H5 subtype by HI assay
  • Representative stains of seasonal H1N1 influenza virus, representative stains of 2009 pandemic H1N1 influenza A virus, representative stains of highly pathogenic H5N1 avian influenza virus and representative stains of seasonal H3N2 influenza virus, which were isolated at different times from different regions and represented different variant types, were selected. HI assay was used to determine the cross-reactivity of the mAb ascites of said 25 monoclonal antibodies with different H subtype of influenza viruses, and three broad-spectrum monoclonal antibodies 12H5, G10D10 and 8F11, which could recognize H1 and H5 subtype of influenza viruses simultaneously, were identified (Table 1). The monoclonal antibody 12H5 could react with seasonal H1 subtype influenza virus, 2009 pandemic H1N1 influenza A virus and H5 subtype avian influenza virus simultaneously, and showed a good broad-spectrum reactivity with different HA subtypes of influenza virus. The monoclonal antibodies G10D10 and 8F11 could react with seasonal H1 subtype influenza virus and H5 subtype avian influenza virus simultaneously, but not with 2009 pandemic H1N1 influenza A virus. However, the monoclonal antibodies G10D10 and 8F11 had a broader reactive spectrum than 12H5 in the case of seasonal H1 subtype influenza virus, could react with both H1 virus isolated in 1930s and H1 virus newly isolated after 2008, had a broader reactive spectrum than 12H5 in the case of H5 subtype avian influenza virus, and could react with more H5N1 virus strains. The results showed that the monoclonal antibodies G10D10 and 8F11 were also good monoclonal antibodies having broad-spectrum reactivity with different HA subtypes of influenza virus. Table 1: Activity of broad-spectrum monoclonal antibody against HA of H1/H5 subtype in HI assay (HI titer)
    Subtype Virus HI titer of mAbs
    12H5 G10D10 8F11
    Seasonal H1N1 A/WSN/1933 ≤100 400 6400
    A/PR/8/1934 ≤100 400 800
    A/Texas/36/1991 6400 ≥12800 ≥12800
    A/HK/134801/1994 ≥12800 ≥12800 3200
    A/Beijing/262/1995 6400 ≥12800 ≥12800
    A/New Calidonia/20/1999 ≥12800 ≥12800 6400
    A/Shantou/104/2005 ≥12800 ≥12800 ≥12800
    A/Xiamen/3115/2006 ≥12800 ≥12800 ≥12800
    A/Xiamen/1128/2006 ≥12800 ≥12800 ≥12800
    A/Solomon Islands/3/2006 800 ≥12800 6400
    A/Brisbane/59/2007 ≥12800 ≥12800 6400
    A/Xiamen/1152/2008 ≥12800 ≥12800 3200
    A/Xiamen/N66/2009 ≤100 3200 3200
    2009 pandemic H1N1 A/California/04/2009 3200 ≤100 ≤100
    A/Xiamen/N514/2009 1600 ≤100 ≤100
    A/HK/MB-1/2010 ≥12800 ≤100 ≤100
    A/HK/402618/2011 3200 ≤100 ≤100
    H5N1 Vietnam/1203/2004 ≤100 1600 1600
    A/Viet Nam/1194/2004 ≤100 1600 1600
    CK/Indonesia/2A/2003 ≤100 3200 3200
    Bar-eaded/Qinghai/15C/2005 1600 ≥12800 ≥12800
    DK/Hunan/101/2004 ≤100 ≥12800 ≥12800
    Ck/HK/YU22/2002 1600 6400 3200
    Seasonal H3N2 A/Brisbane/10/2007 ≤100 ≤100 ≤100
    Note: HI titer refers to the maximum dilution fold at which the ascites can completely inhibit HA activity of virus; wherein ≤100 means no reactivity.
    • Example 3: Evaluation of the broad-spectrum neutralizing activity (Neutralizion titer) of broad-spectrum monoclonal antibodies against HA of H1/H5 subtype by microwell neutralization assay
  • Neutralization activity is an important index for assessing whether a monoclonal antibody has therapeutic potential. Microwell neutralization assay was used to determine the neutralization activity of the monoclonal antibodies 12H5, G10D10 and 8F11 for representative strains of H1N1 and H5N1 subtype influenza viruses (Hulse-Post et al., PNAS. 2005, 102: 10682-7). The results (Table 2) showed that the results of neutralization assay were substantively consistent with the results of HI assay, and the three monoclonal antibodies (12H5, G10D10 and 8F11) had broad-spectrum cross-neutralizing activity with H1N1 and H5N1 viruses. Table 2: Activity of broad-spectrum monoclonal antibodies against HA of H1/H5 subtype in neutralization assay
    Virus subtype/clade Neutralizing titer
    12H5 G10D10 8F11
    A/H K/13480 1/1994 seasonal H1N1 12800 12800 12800
    A/New Calidonia/20/1999 seasonal H1N1 12800 12800 12800
    A/Brisbane/59/2007 seasonal H1N1 3200 12800 12800
    A/California/07/2009 2009 pandemic H1N1 1600 ≤100 ≤100
    A/Xiamen/N514/2009 2009 pandemic H1N1 1600 ≤100 ≤100
    A/HK/MB-1/2010 2009 pandemic H1N1 12800 ≤100 ≤100
    A/HK/402618/2011 2009 pandemic H1N1 3200 ≤100 ≤100
    A/Viet Nam/1194/2004 H5N1 (clade 1) 3200 6400 12800
    A/BHGs/Qinghai/15C/2005 H5N1 (clade 2) 1600 1600 3200
    A/Ck/HK/YU22/2002 H5N1 (clade 8) 1600 12800 12800
    A/Brisbane/10/2007 H3N2 ≤100 ≤100 ≤100
    ≤100, means no reactivity.
    • Example 4: Evaluation of broad-spectrum monoclonal antibody against HA of H1/H5 subtype by blocking-capturing PCR method
  • In order to determine the recognition specificity of broad-spectrum monoclonal antibody, broad-spectrum monoclonal antibody was assayed by blocking-capturing PCR method. The method was as followed.
    • 1. Materials and methods
    1. (1) Ultracentrifuaation of influenza virus: A given amount of seasonal H1N1 influenza virus strain A/New Calidonia/20/1999 (H1N1) was inactivated with 0.03% formalin at 4°C. The inactivated virus was subjected to sucrose density gradient centrifugation in Ultracentrifuge at 4°C, 25200rpm for 3 hours. The virus precipitate was dissolved with 1×PBS at 4°C overnight. The ultracentrifuged virus was subjected to HA detection to determine the titer of the virus solution.
    2. (2) Monoclonal antibodies: broad-spectrum H1 monoclonal antibodies (12H5 and G10D10), unrelated control monoclonal antibody (a monoclonal antibody against HA of type B influenza virus, i.e. anti-Flu B HA mAb 13A12, which cannot bind to H1 subtype of influenza virus A A/NewCalidonia/20/1999); the concentration of monoclonal antibody was 0.5 mg/ml.
    3. (3) NP primers
      upstream primer q-NP-F (SEQ ID NO: 27): 5'-AGT TGG AAC AAT GGT GAT GG-3' downstream primer q-NP-R (SEQ ID NO: 28): 5'-TTC CGG CTC TCT CTC ACT TGA TC-3'
    4. (4) Blocking-capturing PCR assay:
      The monoclonal antibody to be blocked (the coated monoclonal antibody) was pre-coated on polystyrene plate. The blocking monoclonal antibody (the monoclonal antibody to be tested) was mixed with an equal volume of ultracentrifuged virus and incubated at 37°C for 1 hour, and then added to the plate pre-coated with monoclonal antibody. After carrying out the reaction at 37°C for 2 hours, the unbound virus was washed off with conventional washing solution (PBST) for ELISA, and the total RNA of the influenza virus captured on the plate was then extracted by Automated Nucleic Acid Extractor. After reverse transcription of the RNA into cDNA, influenza virus NP gene-specific primer was used for PCR. After 28 cycles of amplification, the PCR amplification product was subjected to agarose gel electrophoresis to determine the ability of the monoclonal antibody to be tested to block the capturing of virus by the coated monoclonal antibody. The more the monoclonal antibody to be tested is similar to the coated monoclonal antibody with respect to the recognition epitope, the higher its blocking ability is, the less the virus captured by the coated monoclonal antibody is, and the weaker the signal of the PCR product determined by electrophoresis is. Quantity One software was finally used to analyze the signal of PCR products quantitatively, and by comparing the fluorescent signal values of the monoclonal antibody to be tested and the unrelated control monoclonal antibody, the mutual blocking rate of the monoclonal antibody to be tested and the coated monoclonal antibody was calculated.
    2. Results and analysis
  • Blocking-capturing PCR method and Quantity One software were used to analyze and determine the blocking rate of PBS, 12H5, G10D10 and 13A12 to block the capture of H1 influenza virus NC20 by monoclonal antibody 12H5, respectively. The results (Figure 1A) showed that H1 monoclonal antibodies 12H5 and G10D10 could well block the capture of NC20 virus by the monoclonal antibody 12H5, while neither of the unrelated monoclonal antibody 13A12 and PBS control could block the capture of NC20 by the monoclonal antibody 12H5. After scanning quantitative analysis by Quantity One software, it was determined that in Figure 1A, the PeaK intxmm value was 1557.323 for Lane 1, 122.286 for Lane 2, 125.807 for Lane 3, 1413.796 for Lane 4, and it was calculated that the corresponding blocking rate was 92.14% for 12H5 vs.12H5, 91.92% for G10D10 vs. 12H5, 9.22% for FluB unrelated monoclonal antibody 13A12 vs. 12H5.
  • By the same method, the blocking rate of PBS, 12H5, G10D10 and FluB-unrelated monoclonal antibody 13A12 to block the capture of H1 influenza virus NC20 by the monoclonal antibody G10D10 were determined. The results (Figure 1B) showed that H1 monoclonal antibody 12H5 and G10D10 could well block the capture of NC20 virus by the monoclonal antibody G10D10, and neither of the unrelated monoclonal antibody 13A12 and PBS control could block the capture of NC20 by the monoclonal antibody 12H5. After scanning quantitative analysis by Quantity One software, it was determined that in Figure 1B, the PeaK intxmm value was 1052.753 for Lane 1, 65.227 for Lane 2, 20.841 for Lane 3, and 923.302 for Lane 4, and it was calculated that the corresponding blocking rate was 93.80% for 12H5 vs. G10D10, 98.02% for G10D10 vs. G10D10, and 12.30% for FluB-unrelated monoclonal antibody 13A12 vs. G10D10.
  • The results showed that the broad-spectrum monoclonal antibodies 12H5 and G10D10 were very similar to each other with respect to the recognition epitope, and therefore 12H5 and G10D10 could block each other to a large extent.
    • Example 5: The epitope recognized by broad-spectrum monoclonal antibodies against HA of H1/H5 subtype was determined as within HA1 domain by analyzing escape mutation.
  • The monoclonal antibodies 12H5, G10D10 and 8F11 were used to induce and screen escape mutants. The positive escape virus thus obtained was purified and subjected to amplification culture, and its gene was obtained, sequenced and was analyzed for the escape mutation site, so as to determine the region in which the epitope recognized by the monoclonal antibodies 12H5, G10D10 and 8F11 was present.
    • 1. Materials and methods:
  • Parent virus: seasonal H1N1 virus A/Brisbane/59/2007 and 2009 pandemic H1N1 virus A/California/07/2009 were selected as parent viruses for escape mutation screening.
    Monoclonal antibodies: 12H5, G10D10 and 8F11
    Escape screening: 105 TCID50 virus was mixed with a monoclonal antibody, and the final concentration of monoclonal antibody was 1mg/ml, with a total volume of 1ml. After incubating at room temperature for 4 hours, the virus-monoclonal antibody complex was used for infecting the MDCK cells pre-plated on a 96-well plate. After incubating the mixture of the virus and monoclonal antibody with the cells for 2 hours, the mixture was taken, and a maintenance medium containing 50ug/ml monoclonal antibody was added, and the cells were cultured at 37°C for 48 h. The culture supernatant was determined by hemagglutination test, the positive virus wells were cloned. After cloning for three times, stable escape viral strains were obtained.
    Localization of escape mutation sites: the obtained escape mutant virus was subjected to RT-PCR for amplification of the structural gene of the virus, and the structural gene thus obtained was sequenced and was aligned with the structural gene of the parent virus to obtain the escape mutation sites.
    • 2 . Results and analysis
  • The results of escape mutation showed that all the escape mutation sites were present in the gene encoding HA1 domain of influenza virus HA protein.
  • In particular, the escape mutation screening results for the monoclonal antibody 12H5 (Table 3) showed that the escape mutation sites involved the amino acid residues at position 138, 142 and 186 (H3 numbering, the same below) of HA1 gene. 5 escape strains were obtained by A/Brisbane/59/2007 (H1N1)-based virus escape screening, and all had mutation at position 142 of HA (N142D); 19 escape strains were obtained by A/California/07/2009 (2009 pandemic H1N1)-based virus escape screening, among which 1 had mutation at position 138 of HA (A138S), 8 had mutation at position 142 of HA (A142E), and the remaining 10 had mutation at position 186 of HA (S186P). Table 3: The amino acid mutation sites of HA from the monoclonal antibody 12H5-induced escape strains
    H1N1 parent virus escape mutation site in HAa
    A/Brisbane/59/2007 N142D(5/5)
    A/California/07/2009 A138S(1/19)
    A 142E(8/19)
    S186P(10/19)
  • The escape mutation screening result for the monoclonal antibody G10D10 (Table 4) showed that the escape mutation site involved the amino acid residue at position 142 of HA1 gene. 4 escape strains were obtained by A/Brisbane/59/2007 (H1N1)-based virus escape screening, and all had mutation at position 142 (N142H for two strains, N142S for one strain and N142Y for one strain). Table 4: The amino acid mutation sites of HA from the monoclonal antibody G10D10-induced escape strains
    H1N1 parent virus escape mutation site in HAa
    A/Brisbane/59/2007 N142H(2/4)
    N142S(1/4)
    N142Y(1/4)
  • The escape mutation screening result for the monoclonal antibody 8F11 (Table 5) showed that the escape mutation site involved the amino acid residue at position 142 of HA1 gene. 5 escape strains were obtained by A/Brisbane/59/2007 (H1N1)-based virus escape screening, and all had mutation at position 142 (N142D for 4 strains, and N142K for one strain). Table 5: The amino acid mutation sites of HA from the monoclonal antibody 8F11-induced escape strains
    H1N1 escape parent virus escape mutation site in HA a
    A/Brisbane/59/2007 N142 D (4/5)
    N142K(1/5)
  • The escape mutation results showed that the monoclonal antibodies 12H5, G10D10, and 8F11 recognized similar epitopes, and the epitopes they recognized were all present in HA1 domain of influenza virus HA protein, and all of them recognized the amino acid at position 142 of HA.
    • Example 6: Separation of light chain gene and heavy chain gene of monoclonal antibodies against HA of H1/H5 subtype
  • About 107 hybridoma cells were cultured by means of semi-adherence, and the adhered cells were suspended by blowing. The suspension was transferred to a new 4 ml centrifuge tube, and centrifuged at 1500 rpm for 3min. The cell precipitate was collected and re-suspended in 100 µl sterile PBS (pH=7.45), and then transferred to a new 1.5 ml centrifuge tube. 800µl Trizol (Roche, Germany) was added, mixed gently by reverse mixing, and then standing for 10min. 200 µl chloroform was added, shaken vigorously for 15s, standing for 10min, and centrifuged at 4°C, 12000rpm for 15min. The supernatant liquid was transferred to a new 1.5ml centrifuge tube, and an equal volume of isopropanol was added, mixed, standing for 10min, and then centrifuged at 4°C, 12000rpm for 10min. The supernatant was removed, 600µl of 75% ethanol was added for washing, and then centrifuged at 4°C, 12000rpm for 5min. The supernatant was removed, and the precipitate was dried under vacuum at 60°C for 5 min. The transparent precipitate was dissolved in 70ul DEPC H2O, and was subpackaged into two tubes. To each tube, 1µl reverse transcription primer was added, wherein the reverse transcription primer added to one tube was MVJkR (5'-CCG TTT GKA TYT CCA GCT TGG TSC C-3') (SEQ ID NO: 19), for amplification of the gene of light chain variable region, and the reverse transcription primer added to the other tube was MVDJhR (5'-CGG TGA CCG WGG TBC CTT GRC CCC A-3') (SEQ ID NO: 20), for amplification of the gene of heavy chain variable region. To each tube, 1µl dNTP (Sangon Biotech (Shanghai) Co.,Ltd.) was added, and the tubes were placed in 72°C water bath for 10min and then immediately in an ice bath for 5min. 10µl 5x reverse transcription buffer, 1µl AMV (10u/ul, Pormega), and 1µl Rnasin (40u/µl, Promega) were added. After mixing the mixture well, RNA was reverse transcripted into cDNA at 42°C.
  • The gene of the variable region of the antibody was isolated by polymerase chain reaction (PCR) method. The primer set synthesized according to Ig-Prime kits of Novagen Company and another two designed and synthesized downstream primers MVJkR, MVDJhR (synthesized by ShangHai Boya Company) were used, wherein MVJkR was a downstream primer for amplification of the gene of light variable region, and MVDJhR was a downstream primer for amplification of the gene of heavy variable region. The templates were the two cDNA as synthesized above. PCR conditions were: 94°C 5min; (94°C 40s, 53°C 1min, 72°C 50s) x 35 cycles ; 72°C 15min. The fragments of interest were recovered and were cloned to pMD 18-T vector, and then were sent to ShangHai Boya Company for sequencing. By blast alignment, the sequences of antibody variable regions were determined, and the corresponding amino acid sequences were determined.
  • By the above method, the genes of the antibody variable regions were cloned from the hybridoma cell lines secreting broad-spectrum monoclonal antibodies 12H5, G10D10 and 8F11, and the corresponding amino acid sequences were determined. Table 6 showed the sequences of the upstream primers used, and Table 7 showed the amino acid sequences of antibody variable regions, and the complementary determinant regions (CDRs) were determined by Kabat method (Kabat EA, Wu TT, Perry HM, Gottesman KS, Coeller K. Sequences of proteins of immunological interest, U.S Department of Health and Human Services, PHS, NIH, Bethesda, 1991). Table 6: Sequences of upstream primers for amplification of variable region genes of the broad-spectrum monoclonal antibodies 12H5, G10D10, and 8F11
    Variable region gene of mAb Name of upstream primer Sequence of upstream primer
    12H5Vh MulgVh5'-D1 (SEQ ID NO: 21) 5'-ATGGRCAGRCTTACWTYYTCATTCCT-3'
    12H5Vk MulgkVl5'-E1 (SEQ ID NO: 22) 5'-ATGTGGGGAYCGKTTTYAMMCTTTTCAATTG-3'
    G10D10Vh MulgVh5'-C2 (SEQ ID NO: 23) 5'-ATGGVTTGGSTGTGGAMCTTGCYATTCCT-3'
    G10D10Vk MulgkVl5'-B (SEQ ID NO: 24) 5'-ATGGAGACAGACACACTCCTGCTAT-3'
    8F11Vh MulgVh5'-C2 (SEQ ID NO: 25) 5'-AtGGVTTGGSTGTGGAMCTTGCYATTCCT-3'
    8F11 Vk MulgkVl5'-G2 (SEQ ID NO: 26) 5'-ATGGTYCTYATVTCCTTGCTGTTCTGG-3'
    Table 7: Amino acid sequences of CDRs of 3 monoclonal antibodies against HA of H1/H5 subtype as identified by Kabat method
    Antibody chain CDR No. Sequences of CDRs of broad-spectrum mAb against H1/H5 subtype
    12H5 G10D10 8F11
    Heavy chain CDR1 GYTFTKNG (SEQ ID NO: 1) GYTFTKYG (SEQ ID NO: 7) GYTFTNYG (SEQ ID NO: 13)
    CDR2 INTYTGEP (SEQ ID NO: 2) INTYTGEP (SEQ ID NO: 8) INTYSGEP (SEQ ID NO: 14)
    CDR3 ARMVRDAMDF (SEQ ID NO: 3) ARMGRDAMDY (SEQ ID NO: 9) ASLRRDAMDH (SEQ ID NO: 15)
    Light chain CDR1 QSVDFDGYNY (SEQ ID NO: 4) QSVDFDGYIY (SEQ ID NO: 10) HSVDFDGYVY (SEQ ID NO: 16)
    CDR2 AAS (SEQ ID NO: 5) AAS (SEQ ID NO: 11) AAS (SEQ ID NO: 17)
    CDR3 QQSNEDPYT (SEQ ID NO: 6) QQSREDPWT (SEQ ID NO: 12) QQSREDPWT (SEQ ID NO: 18)
    • Example 7: Application of broad-spectrum monoclonal antibodies against HA of H1/H5 subtype for detection of influenza virus
  • To determine the effect of said broad-spectrum monoclonal antibodies against HA of H1/H5 subtype for detection of influenza virus, 12H5 and G10D10 were used as representative monoclonal antibodies for the experiment. MDCK cells were infected by representative strains of seasonal H1 subtype influenza virus (A/New Calidonia/20/1999 and A/Brisbane/59/2007), a representative strain of 2009 pandemic H1N1 influenza A virus (A/California/04/2009), and a representative strain of seasonal H3 subtype influenza virus (A/Brisbane/59/2007(H3N2)) as control. The cells were fixed 24h after infection. Immunofluorescence assay was used to analyze the effect of monoclonal antibodies 12H5 and G10D10 for detection of influenza virus. The results (Figure 2) showed that the monoclonal antibody 12H5 had good reactivity with the HA antigens of the two classes of H1 subtype influenza viruses, wherein the fluorescence was mainly observed on cell membrane, and was also observed in cytoplasm. The monoclonal antibody 12H5 had no specific reactivity with H3 subtype influenza virus and negative cells. The monoclonal antibody G10D10 had good reactivity with the HA antigens of the seasonal H1N1 influenza virus, but had no specific reactivity with the 2009 pandemic H1N1 influenza A virus and H3 subtype influenza virus (Figure 3). The results were consistent with the results of HI test and the neutralization assay, indicating that they are useful for detecting influenza virus in cells.
    • Example 8: Application of broad-spectrum monoclonal antibodies against HA of H1/H5 subtype for treatment of influenza virus infection
  • Passive immunotherapy of infectious diseases with antibodies is a potentially effective route for anti-viral treatment. It was demonstrated by in vitro neutralization assay in microwells that the monoclonal antibodies of the invention had high neutralizing activity against H1N1 and H5N1 virus strains isolated from different regions at different times, the monoclonal antibodies were characterized by broad-spectrum H1 neutralizing reactivity, high neutralizing titer, and a good neutralizing effect for some H5. To further demonstrate the anti-viral effect of the monoclonal antibodies in vivo, the in vivo experiment on the anti-viral treatment of H1N1 and H5N1 influenza virus with the monoclonal antibodies was carried out in an Animal Biosafety Level (ABSL)-3 laboratory, based on H1N1 and H5N1 virus-infected animal models, Balb/C mice. The experiment was as followed.
    • (1) Materials and Methods
  • Animal: Balb/C mice, SPF, 6-8 week old, female, weighted about 20g.
  • Monoclonal antibody: 12H5 and G10D10.
  • H1N1 virus:
    • Seasonal H1N1 influenza virus strain A/PuertoRico/8/1934(H1N1), called PR8 for short;
    • A/California/07/2009(H1N1)-MA, a mouse adaptive strain of 2009 pandemic H1N1 influenza A virus stain A/California/07/2009(H1N1), called CA07-MA for short;
    • H5N1 virus: A/Bar-Head Gs/QH/15C/2005 (H5N1), called QH15C for short.
    Anesthetic: Isoflorane
  • Animal grouping: mice were sent to ABSL-3 laboratory one day ahead, and were divided into 4 groups, with 5 mice per cage, designated as G1, G2, ...... etc.; the weight of each mouse was recorded, the regimens were shown in Table 8.
  • Virus infection: H5 virus QH15C was pre-diluted to 103 TCID50/µl, H1 viruses RP8 and CA04-MA were pre-diluted to 105 TCID50/µl, the mice were inoculated with the virus at 25µl/mouse. Before inoculation, mice were anesthetized with isoflorane, and then infected by inoculation of virus via nasal cavity.
  • MAb intervention: 24h (dpi.1) after virus infection, the mice in antibody-treatment group were injected with antibody at different doses, i.e. 20mg/kg, 10mg/kg, 5mg/kg and 2.5mg/kg, respectively, wherein the injection volume was100µl/mouse.
  • Observation: 1-14 days after virus infection, weight, survival, and the corresponding behavioral symptoms of mice were recorded every day. Table 8. Regimen of anti-viral treatment with broad-spectrum monoclonal antibody
    Group Note Infectious virus mAb intervention Number of mice
    12H5 treatment regimen
    G1 Blank control group PBS PBS 5
    G2 H1 virus control group CA07-MA PBS 5
    G3 H1 treatment group 1 CA07-MA 12H5 10mg/kg 5
    G4 H1 treatment group 2 CA07-MA 12H5 5mg/kg 5
    G5 H1 treatment group 3 CA07-MA 12H5 2.5mg/kg 5
    G6 H5 virus control group QH15C PBS 5
    G7 H5 treatment group 1 QH15C 12H5 10mg/kg 5
    G8 H5 treatment group 2 QH15C 12H5 5mg/kg 5
    G9 H5 treatment group 3 QH15C 12H5 2.5mg/kg 5
    G10D10 treatment regimen
    G10 Blank control group PBS PBS 5
    G11 H1 virus control group PR8 PBS 5
    G12 H1 treatment group PR8 G10D10 20mg/kg 5
    G13 H5 virus control group QH15C PBS 5
    G14 H5 treatment group 1 QH15C 12H5 10mg/kg 5
    G15 H5 treatment group 2 QH15C 12H5 5mg/kg 5
    G16 H5 treatment group 3 QH15C 12H5 2.5mg/kg 5
    • (2) Results and analysis
  • Mice were separately infected by CA7 virus of 2009 pandemic H1N1 and H5N1 virus strain QH15C at a one-week lethal dose. Antibody intervention was initiated 1 day after infection. The treatment effect of monoclonal antibody was determined by measuring the body weight and calculating the survival rate (Figure 4). It could be seen that no significant weight fluctuation was observed in negative control group during the experiment; significant weight loss was observed in two virus control groups, all the mice died 6 days after infection in CA07 virus control group, and all the mice died 9 days after infection in QH15C virus control group. In the case of said two viruses, 12H5 antibody intervention at different doses leaded to weight recovery in mice (Figures 4A and 4C). It could be found by observing the survival of mice during 1-14 days after virus infection that the treatment with 12H5 monoclonal antibody at a dose of 10mg/kg and 5mg/kg could enable the mice infected by said two viruses survive normally for 14 days, and the treatment effect reached 100%, whereas 12H5 at a dose of 2.5mg/kg could not completely protect the mice and the treatment effect was 60% for said two viruses (Figures 4B and 4D). The results showed that 12H5 also had a good protective effect at a low dose (5mg/Kg).
    Mice were separately infected by H5N1 virus strain QH15C and seasonal influenza virus strain PR8 (recent seasonal H1N1 virus was not pathogenic to mice, and therefore early H1N1 virus strain PR8 pathogenic to mice was used in this experiment) at a one-week lethal dose, and used for evaluating the treatment effect of the monoclonal antibody G10D10. Since the monoclonal antibody G10D10 had a weak activity for PR8 (HI titer was only 400), a high dose (20mg/kg) was used in the animal experiment. The results (Figure 5) showed that the monoclonal antibody G10D10 had a better therapeutic effect than the monoclonal antibody 12H5 in the case of H5 virus, wherein the mice could regain weight when treated with the antibody at any of the three doses (Figure 5A), and the survival of mice was 100% (Figure 5B). In the case of PR8 virus, G10D10 monoclonal antibody intervention at a dose of 20mg/kg could also effectively relieve weight loss in mice (Figure 5C), and finally make 80% of mice survive (Figure 5D), indicating that the monoclonal antibody G10D10 also had a broad-spectrum anti-viral therapeutic effect.
  • Although the specific embodiments of the invention have been described in detail, those skilled in the art would understand that, according to all the disclosed teachings, various modifications and changes can be made, and that such modifications and changes are within the scope of the present invention. The scope of the present invention is given by the appended claims and any equivalents thereof.
    • SEQUENCE LISTING
    • <110> XIAMEN UNIVERSITY
    • <120> Broad-spectrum monoclonal antibody recognizing HA1 domain of hemagglutinin of influenza virus
    • <130> BET 15M2680
    • <140> EP14778269.2
      <141> 2014-04-02
    • <150> CN 201310113101.5
      <151> 2013-04-02
    • <160> 28
    • <170> PatentIn version 3.5
    • <210> 1
      <211> 8
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> heavy chain CDR1 of 12H5
    • <400> 1
      Figure imgb0001
    • <210> 2
      <211> 8
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> heavy chain CDR2 of 12H5
    • <400> 2
      Figure imgb0002
    • <210> 3
      <211> 10
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> heavy chain CDR3 of 12H5
    • <400> 3
      Figure imgb0003
    • <210> 4
      <211> 10
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> light chain CDR1 of 12H5
    • <400> 4
      Figure imgb0004
    • <210> 5
      <211> 3
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> light chain CDR2 of 12H5
    • <400> 5
      Figure imgb0005
    • <210> 6
      <211> 9
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> light chain CDR3 of 12H5
    • <400> 6
      Figure imgb0006
    • <210> 7
      <211> 8
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> heavy chain CDR1 of G10D10
    • <400> 7
      Figure imgb0007
    • <210> 8
      <211> 8
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> heavy chain CDR2 of G10D10
    • <400> 8
      Figure imgb0008
    • <210> 9
      <211> 10
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> heavy chain CDR3 of G10D10
    • <400> 9
      Figure imgb0009
    • <210> 10
      <211> 10
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> light chain CDR1 of G10D10
    • <400> 10
      Figure imgb0010
    • <210> 11
      <211> 3
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> light chain CDR2 of G10D10
    • <400> 11
      Figure imgb0011
    • <210> 12
      <211> 9
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> light chain CDR3 of G10D10
    • <400> 12
      Figure imgb0012
    • <210> 13
      <211> 8
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> heavy chain CDR1 of 8F11
    • <400> 13
      Figure imgb0013
    • <210> 14
      <211> 8
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> heavy chain CDR2 of 8F11
    • <400> 14
      Figure imgb0014
    • <210> 15
      <211> 10
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> heavy chain CDR3 of 8F11
    • <400> 15
      Figure imgb0015
    • <210> 16
      <211> 10
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> light chain CDR1 of 8F11
    • <400> 16
      Figure imgb0016
    • <210> 17
      <211> 3
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> light chain CDR2 of 8F11
    • <400> 17
      Figure imgb0017
    • <210> 18
      <211> 9
      <212> PRT
      <213> Artificial sequence
    • <220>
      <223> light chain CDR3 of 8F11
    • <400> 18
      Figure imgb0018
    • <210> 19
      <211> 25
      <212> DNA
      <213> Artificial sequence
    • <220>
      <223> primer
    • <400> 19
      ccgtttgkat ytccagcttg gtscc   25
    • <210> 20
      <211> 25
      <212> DNA
      <213> Artificial sequence
    • <220>
      <223> primer
    • <400> 20
      cggtgaccgw ggtbccttgr cccca   25
    • <210> 21
      <211> 26
      <212> DNA
      <213> Artificial sequence
    • <220>
      <223> primer
    • <400> 21
      atggrcagrc ttacwtyytc attcct   26
    • <210> 22
      <211> 31
      <212> DNA
      <213> Artificial sequence
    • <220>
      <223> primer
    • <400> 22
      atgtggggay cgktttyamm cttttcaatt g   31
    • <210> 23
      <211> 29
      <212> DNA
      <213> Artificial sequence
    • <220>
      <223> primer
    • <400> 23
      atggvttggs tgtggamctt gcyattcct   29
    • <210> 24
      <211> 25
      <212> DNA
      <213> Artificial sequence
    • <220>
      <223> primer
    • <400> 24
      atggagacag acacactcct gctat   25
    • <210> 25
      <211> 29
      <212> DNA
      <213> Artificial sequence
    • <220>
      <223> primer
    • <400> 25
      atggvttggs tgtggamctt gcyattcct   29
    • <210> 26
      <211> 27
      <212> DNA
      <213> Artificial sequence
    • <220>
      <223> primer
    • <400> 26
      atggtyctya tvtccttgct gttctgg   27
    • <210> 27
      <211> 20
      <212> DNA
      <213> Artificial sequence
    • <220>
      <223> primer
    • <400> 27
      agttggaaca atggtgatgg   20
    • <210> 28
      <211> 23
      <212> DNA
      <213> Artificial sequence
    • <220>
      <223> primer
    • <400> 28
      ttccggctct ctctcacttg atc   23

Claims (16)

  1. A monoclonal antibody or an antigen binding fragment thereof, which can specifically bind to HA1 domain of different HA subtypes of influenza virus and specifically bind to HA1 domain of HA protein of H1 subtype and H5 subtype of influenza viruses, wherein the monoclonal antibody or an antigen binding fragment thereof has the heavy chain and light chain CDRs selected from the group consisting of:
    1) the heavy chain CDR1-3 set forth in SEQ ID NOs: 1-3, and the light chain CDR1-3 set forth in SEQ ID NOs: 4-6;
    2) the heavy chain CDR1-3 set forth in SEQ ID NOs: 7-9, and the light chain CDR1-3 set forth in SEQ ID NO: 10-12; and
    3) the heavy chain CDR1-3 set forth in SEQ ID NOs: 13-15, and the light chain CDR1-3 set forth in SEQ ID NO: 16-18.
  2. The monoclonal antibody or antigen binding fragment thereof according to claim 1, wherein the monoclonal antibody or antigen binding fragment thereof has one or more of the following features:
    (1) the monoclonal antibody is the following monoclonal antibody: the monoclonal antibody produced by hybridoma cell line 12H5 or G10D10 or 8F11, wherein the hybridoma cell lines 12H5, G10D10 and 8F11 are deposited in China Center for Type Culture Collection (CCTCC), and have a deposition number of CCTCC NO: C201230, CCTCC NO: C201229 and CCTCC NO: C2013119, respectively;
    (2) the monoclonal antibody or antigen binding fragment thereof is selected from Fab, Fab', F(ab')2, Fd, Fv, single chain antibody, mouse antibody, humanized antibody, chimeric antibody, or bispecific or poly-specific antibody;
    (3) the monoclonal antibody comprises non-CDR region, and the non-CDR region is from species other than murine species.
  3. The monoclonal antibody or antigen binding fragment thereof according to claim 2, wherein the single chain antibody is scFv.
  4. The monoclonal antibody or antigen binding fragment thereof according to claim 2, wherein the chimeric antibody is human mouse chimeric antibody.
  5. The monoclonal antibody or antigen binding fragment thereof according to claim 2, wherein the non-CDR region is from human antibody.
  6. An isolated nucleic acid molecule, encoding the monoclonal antibody or antigen binding fragment thereof according to anyone of claims 1-5.
  7. A vector, comprising the isolated nucleic acid molecule according to claim 6.
  8. A host cell, comprising the isolated nucleic acid molecule according to claim 6 or the vector according to claim 7.
  9. A hybridoma cell line, which is selected from the group consisting of:
    1) a hybridoma cell line 12H5, deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO: C201230;
    2) a hybridoma cell line G10D10, deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO: C201229; and
    3) a hybridoma cell line 8F11, deposited in China Center for Type Culture Collection (CCTCC), with a deposition number of CCTCC NO: C2013119.
  10. A pharmaceutical composition, comprising the monoclonal antibody or antigen binding fragment thereof according to anyone of claims 1-5, and a pharmaceutically acceptable carrier and/or excipient.
  11. A pharmaceutical composition, comprising the isolated nucleic acid molecule according to claim 6 or the vector according to claim 7, and a pharmaceutically acceptable carrier and/or excipient.
  12. A method for producing the monoclonal antibody or antigen binding fragment thereof according to anyone of claims 1-5, comprising:
    1) expressing the isolated nucleic acid molecule according to claim 6 or the vector according to claim 7 in a host cell, to produce the monoclonal antibody or antigen binding fragment thereof; and
    2) isolating the monoclonal antibody or antigen binding fragment thereof.
  13. A method for detecting in vitro the presence or level of HA protein of H1 subtype and/or H5 subtype influenza virus in a sample, comprising the use of the monoclonal antibody or antigen binding fragment thereof according to anyone of claims 1-5.
  14. A method for diagnosing whether a subject is infected by H1 subtype and/or H5 subtype influenza virus, comprising using the monoclonal antibody or antigen binding fragment thereof according to anyone of claims 1-5 to detect the presence of H1 subtype and/or H5 subtype influenza virus in a sample derived from the subject.
  15. The monoclonal antibody or antigen binding fragment thereof according to anyone of claims 1-5, for use in preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection.
  16. The monoclonal antibody or antigen binding fragment thereof for use according to claim 15, wherein the disease caused by the infection is influenza.
EP14778269.2A 2013-04-02 2014-04-02 Broad spectrum monoclonal antibody identifying ha1 structural domain of influenza virus hemagglutinin proteins Active EP2982691B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310113101 2013-04-02
PCT/CN2014/074612 WO2014161483A1 (en) 2013-04-02 2014-04-02 Broad spectrum monoclonal antibody identifying ha1 structural domain of influenza virus hemagglutinin proteins

Publications (3)

Publication Number Publication Date
EP2982691A1 EP2982691A1 (en) 2016-02-10
EP2982691A4 EP2982691A4 (en) 2016-11-23
EP2982691B1 true EP2982691B1 (en) 2020-05-06

Family

ID=51657607

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14778269.2A Active EP2982691B1 (en) 2013-04-02 2014-04-02 Broad spectrum monoclonal antibody identifying ha1 structural domain of influenza virus hemagglutinin proteins

Country Status (5)

Country Link
US (1) US9650434B2 (en)
EP (1) EP2982691B1 (en)
CN (1) CN104098692B (en)
HK (1) HK1214834A1 (en)
WO (1) WO2014161483A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6772157B2 (en) * 2015-02-05 2020-10-21 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Binding molecule to influenza hemagglutinin and its use
WO2016192652A1 (en) * 2015-06-03 2016-12-08 厦门大学 Broad-spectrum monoclonal anti-flu b antibody and uses thereof
CN106928350B (en) * 2015-12-30 2020-11-03 中国科学院天津工业生物技术研究所 Influenza virus antibody, preparation method and application thereof
RU2770860C2 (en) * 2016-04-18 2022-04-22 Верситек Лимитед Cold-adapted live attenuated virulence factor-removed vaccine suitable for mucosal delivery
EP3699186A4 (en) * 2017-10-18 2021-12-15 Xiamen University Mutant of h3n2 subtype influenza virus hemagglutinin protein and use thereof
CL2018003871A1 (en) 2018-12-28 2021-01-15 Univ Pontificia Catolica Chile Monoclonal antibodies specific for human influenza virus (flu) pb2 antigen, nucleotide sequences; flu infection diagnostic method and kit
CN112159468B (en) * 2020-09-23 2022-05-17 浙江大学医学院附属第一医院 anti-H1N 1 influenza virus hemagglutinin protein monoclonal antibody ZJU-A1 with neutralization activity
CN114957456B (en) * 2022-05-28 2024-03-12 浙江大学医学院附属第一医院 Monoclonal antibody ZJU-A1A3 of influenza A virus hemagglutinin protein and application thereof in detection
CN117487003A (en) * 2022-08-02 2024-02-02 东莞市朋志生物科技有限公司 Anti-influenza B virus antibody or functional fragment thereof, and reagent and kit for detecting influenza B virus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2008028946A2 (en) * 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
CN102216327A (en) * 2008-07-25 2011-10-12 生物医学研究所 Neutralizing anti-influenza a virus antibodies and uses thereof
JP2012526839A (en) 2009-05-13 2012-11-01 シー レーン バイオテクノロジーズ， エルエルシー Neutralizing molecule against influenza virus
US9534042B2 (en) * 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
US20130289246A1 (en) 2010-09-30 2013-10-31 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
GB201115214D0 (en) 2011-09-02 2011-10-19 Health Prot Agency Influenza virus antibody compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
CN104098692B (en) 2018-11-30
WO2014161483A1 (en) 2014-10-09
US20160145320A1 (en) 2016-05-26
US9650434B2 (en) 2017-05-16
EP2982691A1 (en) 2016-02-10
CN104098692A (en) 2014-10-15
HK1214834A1 (en) 2016-08-05
EP2982691A4 (en) 2016-11-23

Similar Documents

Publication Publication Date Title
EP2982691B1 (en) Broad spectrum monoclonal antibody identifying ha1 structural domain of influenza virus hemagglutinin proteins
EP2975052B1 (en) Epitope of rsv fusion protein and antibody identifying same
US9598482B2 (en) Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes
US10696736B2 (en) Broad-spectrum monoclonal anti-flu B antibody and uses thereof
US10973905B2 (en) Cross-protective pathogen protection, methods and compositions thereof
KR20140112495A (en) Influenza a virus specific antibodies
CN107674123B (en) Anti-idiotype antibody and application thereof
KR20160068636A (en) Adjuvant composition comprising one or more influenza virus neutralizing binding molecules and vaccine composition comprising thereof
CN111094335A (en) Broadly neutralizing anti-influenza monoclonal antibodies and uses thereof
US20220242935A1 (en) Pan-neuraminidase inhibiting antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151002

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1214834

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20161026

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/20 20060101ALI20161020BHEP

Ipc: C07K 16/10 20060101AFI20161020BHEP

Ipc: C12N 15/13 20060101ALI20161020BHEP

Ipc: A61K 39/42 20060101ALI20161020BHEP

Ipc: C12N 15/63 20060101ALI20161020BHEP

Ipc: A61P 31/16 20060101ALI20161020BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190228

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200107

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1266583

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014065081

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200807

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200806

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200906

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200907

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200806

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1266583

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014065081

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20210209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210402

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20210430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210430

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20140402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230628

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240222

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240308

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240227

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506